

J Med Chem. Author manuscript; available in PMC 2012 September 25

Published in final edited form as:

J Med Chem. 1995 March 31; 38(7): 1174-1188.

Search for New Purine- and Ribose-Modified Adenosine Analogues as Selective Agonists and Antagonists at Adenosine Receptors[†]

Suhaib M. Siddiqi[‡], Kenneth A. Jacobson^{*,‡}, John L. Esker[⊥], Mark E. Olah[¶], Xiao-duo Ji[‡], Neli Melman[‡], Kamal N. Tiwari[§], John A. Secrist III[§], Stewart W. Schneller[∥], Gloria Cristalli[▽], Gary L. Stiles[¶], Carl R. Johnson[⊥], and Ad P. IJzerman[∞] Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes, and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810, Organic Chemistry Research Department, Southern Research Institute, P.O. Box 55305, Birmingham, Alabama 35255-5305, Department of Chemistry, Wayne State University, Detroit, Michigan 48202-3489, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, Departmento di Scienze Chimiche, Università di Camerino, 62032 Camerino, Italy, Leiden / Amsterdam Center for Drug Research, Division of Medicinal Chemistry, P.O. Box 9502, 2300 RA Leiden, The Netherlands, and Department of Chemistry, 179 Chemistry Building, Auburn University, Auburn, Alabama 36849-5312

Abstract

The binding affinities at rat A_1 , A_{2a} , and A_3 adenosine receptors of a wide range of derivatives of adenosine have been determined. Sites of modification include the purine moiety (1-, 3-, and 7-deaza; halo, alkyne, and amino substitutions at the 2- and 8-positions; and N^6 -CH₂-ring, - hydrazino, and -hydroxylamino) and the ribose moiety (2'-, 3'-, and 5'-deoxy; 2'- and 3'-O-methyl; 2'-deoxy 2'-fluoro; 6'-thio; 5'-uronamide; carbocyclic; 4'- or 3'-methyl; and inversion of configuration). (-)- and (+)-5'-Noraristeromycin were 48- and 21-fold selective, respectively, for A_{2a} vs A_1 receptors. 2-Chloro-6'-thioadenosine displayed a K_i value of 20 nM at A_{2a} receptors (15-fold selective vs A_1). 2-Chloroadenin-9-yl(β -L-2'-deoxy-6'-thiolyxofuranoside) displayed a K_i value of 8 μ M at A_1 receptors and appeared to be an antagonist, on the basis of the absence of a GTP-induced shift in binding vs a radiolabeled antagonist (8-cyclopentyl-1,3-dipropylxanthine). 2-Chloro-2'-deoxyadenosine and 2-chloroadenin-9-yl(β -D-6'-thioarabinoside) were putative partial agonists at A_1 receptors, with K_i values of 7.4 and 5.4 μ M, respectively. The A_{2a} selective agonist 2-(1-hexynyl)-5'-(N-ethylcarbamoyl)adenosine displayed a K_i value of 26 nM at A_3 receptors. The 4'-methyl substitution of adenosine was poorly tolerated, yet when combined with

[†]Abbreviations: AB-MECA, N^6 -(4-aminobenzyl)adenosine-5'-(N-methyluronamide; CGS 21680, 2-[[[4-(2-carboxyethyl)phenyl]ethyl]-amino]-5'-(N-ethylcarbamoyl)adenosine; CHA, N^6 -cyclohexyladenosine; CHO, Chinese hamster ovary; CPA, N^6 -cyclopentyladenosine; CPX, 8-cyclopentyl-1,3-dipropylxanthine; DMAP, 4-(dimethylamino)pyridine; DMF, N-dimethylformamide; DMSO, dimethyl sulfoxide; EtOH, ethanol; HE-NECA, 2-(1-hexynyl)-5'-(N-ethylcarbamoyl)adenosine; HMDS, hexamethyldisilazane; MeOH, methanol; MeCN, acetonitrile; NECA, 5'-(N-ethylcarbamoyl)adenosine; PIA, (N- N^6 -(phenylisopropyl)-adenosine; THF, tetrahydrofuran; TMS, trimethylsilyl; TMS-OTf, trimethylsilyl trifluoromethanesulfonate; Tris, tris(hydroxymethyl)-aminomethane.

^{*}Address correspondence to Dr. Kenneth A. Jacobson, Bldg. 8A, Rm. B1A-17, MRS/LBC/NIDDK/NIH, 8 Center Dr., MSC 0810, Bethesda, MD 20892-0810. Tel.: (301) 496-9024. Fax: (301) 402-0008.

National Institutes of Health.

[§]Southern Research Institute.

[⊥]Wayne State University.

Auburn University.

[♥]Università di Camerino.

[¶]Duke University Medical Center.

[∞]Leiden/Amsterdam Center for Drug Research.

other favorable modifications, potency was restored. Thus, N^6 -benzyl-4'-methyladenosine-5'-(N^6 -methyluronamide) displayed a K_i value of 604 nM at A_3 receptors and was 103- and 88-fold selective vs A_1 and A_{2a} receptors, respectively. This compound was a full agonist in the A_3 -mediated inhibition of adenylate cyclase in transfected CHO cells. The carbocyclic analogue of N^6 -(3-iodobenzyl)adenosine-5'-(N^6 -methyluronamide) was 2-fold selective for A_3 vs A_1 receptors and was nearly inactive at A_{2a} receptors.

Introduction

The adenosine receptors are members of the super-family of receptors coupled to guanyl nucleotide-binding proteins (G-proteins). The are composed of seven transmembrane helical domains. Adenosine mediates a wide variety of physiological functions including vasodilatation, vasoconstriction in the kidney, cardiac depression, inhibition of lipolysis, inhibition of platelet aggregation, inhibition of lymphocyte functions, inhibition of insulin release and potentiation of glucagon release in the pancreas, inhibition of neurotransmitter release from nerve endings, stimulation of steroidogenesis, and potentiation of histamine release from mast cells. The A_1 , A_{2a} , A_{2b} , and A_3 adenosine receptors have been cloned from several species, including in each case rat, dog, mouse, and human. Activation of A_1 and A_3 receptors causes the inhibition of adenylate cyclase, activation of phospholipase C, activation of potassium channels, and inhibition of calcium channels. The A_{2a} and A_{2b} receptors activate adenylate cyclase via G-protein coupling.

Numerous structure—activity relationship studies of adenosine responses have been published (see ref 1). The objectives of these studies have been to discover highly potent analogues of adenosine, long-acting and nonmetabolizable agonists and antagonists, and analogues which are specific for a subtype of adenosine receptors. The recent discovery of the novel rat A_3 adenosine receptor subtype⁷ prompted us to undertake a detailed examination of a variety of nucleoside analogues as ligands for A_3 and other adenosine receptors. Agents selective for A_3 receptors^{8–10} have promise as agents for treating ischemia of the brain and heart, ^{11,12} inflammation, and asthma. ¹³ This study is a survey of some known and some novel modifications of adenosine to identify structural changes that result in selectivity.

Since some adenine and adenosine derivatives have been shown to be adenosine receptor antagonists, 15,26 we have examined potential new leads for adenosine derivatives as selective antagonists. A selective antagonist at the rat A_3 receptor is lacking. Several xanthine analogues that act as the potent antagonists at rat, rabbit, and human A_1 and A_2 receptors only weakly displaced the binding of radioligand from cloned rat A_3 receptors. 16

Results Chemistry

Adenosine analogues containing a variety of structural modification (compounds **1–44**) were examined in this study. The affinity of the adenosine analogues at A_1 , A_{2a} , and A_3 receptors was established in binding assays $^{17-19}$ (Table 1). Physical data for new adenosine analogues are listed in Table 2. Compounds ${\bf 10b}^{24b}$ and ${\bf 12b}^{52}$ were prepared according to literature-known procedures.

The synthesis of the carbocyclic derivative 12c is shown in Scheme 1. Using a procedure that has been employed to couple cyclopentyl acetates with nucleophiles in the presence of Pd(0) catalysis to give *cis*-oriented products, 20 reaction of (+)-45 with 2,6-dichloropurine gave (+)-46. Standard vicinal glycolization of (+)-46 to (-)-47 was followed by exchanging the 6-chloro group with NH₄OH to give 48. Heating 48 with phenylethylamine gave 12c.

3'-C-Methyladenosine, **29a**, and 4'-C-methyladenosine, **29b**, were prepared according to known procedures. ^{49,50} The 4'-C-methyl modification was combined with other substitutions known to favor A₃ selectivity (Scheme 2). The methyl 4-methyl-Dribofuranoside uronate 49 was prepared previously as an intermediate in the chemoenzymatic synthesis of methyl 4-methyl-D-ribofuranoside from cyclopentadiene. ²¹ This methyl uronate was transformed into the corresponding nucleoside. Direct amidation proceeded smoothly with methylamine in MeOH to give the methyl amide 50, which was converted to the diacetate 51 by treatment with HCl/MeOH and acetylation with acetic anydride and pyridine. When the β -methyl glycoside 51 was subjected to Vorbrüggen conditions²² (N⁹-TMS-6-chloropurine, TMS-OTf, CH₃CN, 50 °C), a significant amount of the α -nucleoside was initially formed even though the 2-acetyl group is β -directing. Apparently the carbonyl of the uronamide can participate as an α -director. However, upon heating to 80 °C for 6–12 h, the thermodynamically more stable β -nucleoside 52 was formed in good yield as the sole product. When the displacement of the chloro group with benzylamine was conducted in methanol at 70 °C, 1–2% of the 6-methoxy derivative contaminated the product. The use of tert-butyl alcohol instead of methanol as cosolvent suppressed this type of reaction and gave clean N-benzyl-adenosinuronamide 41.

An N^6 -substituted 5'-uronamide, **42**, was synthesized following the approach of Gallo-Rodriguez et al.⁸ via the action of furfurylmethylamine on 6-chloropurine-5'-(N-methyluronamido)riboside 2',3'-dimethylacetal, **53**. Deblocking the 2',3'-dimethylacetal protecting group was sluggish due to the acid-sensitive nature of the furfuryl group.

The synthesis of the carbocyclic analogue (\pm) -44 (Scheme 3) began by heating (\pm) -54 with methylamine to provide (\pm) -55. Reaction of 55 with 5-amino-4,6-dichloropurine gave intermediate 56. Heating 56 with methyl dimethoxyacetate followed by acidic treatment gave 57. The 6-chloro group of 57 was displaced by 3-iodobenzylamine to give 44.

Synthesis of **12a** (Scheme 4) was accomplished by employing a standard procedure for preparing carbocyclic nucleosides. ⁵⁶ Thus, reaction of (\pm) -trans-2-aminocyclopentanol with 2-amino-4,6-dichloropyrimidine yielded **65**, which was subjected to C-5 diazo coupling with 4-(chlorophenyl)diazonium chloride to result in **66**. Completion of the preparation of **12a** followed a routine sequence: ⁵⁶ reduction of **66** to amine **67**, ring closure with trimethyl orthoformate to prepare precursor **68**, and, finally, displacement of chlorine by ammonia to give **12a**.

The synthesis of the carbocyclic **15b** began with the reaction of N-[4-(1-butyl)phenyl]guanidine nitrate with diethyl allylmalonate to give **58** (Scheme 5) plus a small amount of the isomeric **59**.⁵³ To achive successful chlorination of **58** to **60**, it was necessary to add tetraethylammonium chloride to the phosphorus oxychloride. In our hands, the standard ozonolysis approach for converting the allyl side chain of **60** to the acetaldehyde substituent of **61** could not be accomplished, apparantly due to susceptibility of the arylamino side chain to the reaction conditions. Thus, treatment of **60** with osmium tetraoxide in the presence of sodium periodate yielded **61** that was, in turn, readily converted into its dimethyl acetal derivative **62**. Reaction of **62** with (\pm) - 4α -amino- 2β , 3α -dihydroxy- 1α -cyclopentanemethanol⁵⁴ provided **63**. The latter product was not fully characterized but was ring closed under acidic conditions to **64** that was then converted into the target derivative **15b** by heating with methanolic ammonia.

Biology

2-Chloroadenosine, $\mathbf{1}$, was much more potent than 1-deaza-2-chloroadenosine, $\mathbf{2}$, at A_1 receptors and nearly equipotent at A_3 receptors. Thus, the 1-deaza modification is well

tolerated at rat A_3 receptors. Among 2-halo analogues, the difference in affinity between 2-chloro- and 2-fluoroadenosine was most pronounced at A_3 receptors, at which the 2-fluoro analogue **3** was 5.5-fold less potent. As shown previously, certain 8-position substitution, such as bromo, **4**, was not well tolerated at A_3 receptors, and the potencies of the 8-amino and 8-butylamino analogues²³ **5** and **6**, respectively, were consistent with this observation. There was a slight tendency toward A_{2a} selectivity among compounds **4–6**.

Carbocyclic nucleosides have found wide application in the antiviral area.²⁴ At adenosine receptors, there are few reports of the affinity of carbocyclic derivatives of adenosine. Francis et al.²⁵ reported that the carbocyclic analogue of CGS 21680, an A_{2a} selective agonist, retained that selectivity. Racemic aristeromycin was reported to have activity at A_{2b} receptors. ²⁶ Enantiomerically pure aristeromycin, **7**, isolated from *Streptomyces citricolor*, ²⁷ showed essentially no displacement of radioligand from A₁ or A_{2a} receptors but was weakly potent at A₃ receptors. The 5'-deoxy modification of adenosine, shown previously to be tolerated at A₁, A_{2a}, and A₃ receptors, was somewhat compatible with the carbocyclic modification at A_{2a} and A₃ receptors. 5'-Deoxyaristeromycin, ²⁸ **9**, was only 7-fold less potent than 5'-deoxyadenosine, 8, at A_{2a} receptors and of comparable potency to aristeromycin, 7, at A₃ receptors. Curiously, by deleting the 5'-methylene group of aristeromycin, as in compound 10a ((-)-5'-noraristeromycin), the potency was greatly enhanced at A_1 and A_{2a} receptors. The K_i value of 10a at A_{2a} receptors was 0.69 μ M, and there was also selectivity vs A_1 (48-fold) and A_3 receptors. This prompted us to synthesize an analogue which contained a 2-(2-phenylethyl)amino group, found previously to be conducive to A_2 selectivity, 18,25 as in compound 11. The two sets of modifications however were not additive at A2a receptors, and the hybrid compound 12c was nearly equipotent at A₁ and A_{2a} receptors. With the 2-(2-phenylethyl)amino group, there was no decrease in affinity at A_1 receptors from the 5'-norcarbocyclic modification. The same carbocyclic modification nearly abolished affinity at all adenosine receptors when combined with the 3deaza modification (cf. 13 and 14). Didehydrodideoxy and dideoxy analogues of carbocyclic nucleosides $10b^{24b}$ and 12a were inactive at A_1 , and they were marginally active at A_{2a} and A_3 receptors. Dideoxy-3-oxa derivative $12b^{52}$ was nearly inactive at A_1 receptors, but it showed very weak binding affinity to A_{2a} and A_3 receptors. 3-Deazaadenosine, 13, itself, was only weakly potent at the three subtypes. Similarly 7-deazaadenosine, 15a, was only marginally potent, and in combination with the 5'- and carbocyclic modifications was essentially inactive in binding. 7-Deaza-2-(phenylbutyl)-ara-aristeromycin, 15b, was only weakly potent at the three sybtypes, and there was also selectivity for A₃ vs A₁ and A_{2a} receptors.

 β -L-Adenosine, compound 17, was shown to bind weakly to A_1 receptors. Curiously, compound 18 ((+)-5'-noraristeromycin), the L-analogue of compound 10a, showed considerable potency at A_{2a} (> A_1 and A_3) receptors and was 21-fold selective for A_{2a} vs A_1 receptors. The 6'-thio modification of adenosine was well tolerated in receptor binding. (The position corresponding to the carbohydrate 4'-oxygen is here numbered 6', as in carbocyclic derivatives.) Compound 19 was 3.2-fold more potent than the corresponding oxygen analogue 1 at A_{2a} receptors, while at A_1 receptors affinity diminished by 32-fold. Compounds 1 and 19 were of similar potency at A_3 receptors. Thus, this thio modification, which provided 15-fold selectivity in 19, may serve as a means of increasing A_{2a} selectivity in general. The 6'-thio and 2-chloro modifications of the arabinoside resulted in a substantial gain in potency at all three subtypes (cf. 21 and 20). Surprisingly, even the 2'-deoxy-6'-thio-L-xylofuranoside analogue 22 had potency comparable to 21 at A_1 and A_{2a} receptors.

Compounds **23–29** contain 2'- and 3'-ribose modifications. The 2'-deoxy-2'-fluoro modification of 2-chloroadenosine, 30 **23**, had K_i values at A_1 and A_{2a} receptors in the

micromolar range and was 2 orders of magnitude less potent at A_3 receptors. The degree of tolerance of the 2'-fluoro substituent (cf. compound 1) was greatest at A_{2a} receptors. The corresponding 2'-deoxy analogue 25^{46} was less potent than 23 at A_1 and A_{2a} receptors by factors of 11 and 23. Thus at the 2'-position substituents in the order OH > F > H are favored in receptor binding at all three subtypes. For purposes of this comparison, it was essential to have the potency-enhancing 2-chloro substituent in order to obtain measurable K_i values (cf. compound 24, which was nearly inactive).

The 1-deaza modification of adenosine was already shown to be tolerated in receptor binding (see compound 2). Deletion of the 2'-hydroxy group of 2, resulting in compound 26, was poorly tolerated in receptor binding. Only at A_1 receptors was there a measurable K_i value (29 μ M). Deletion of both 2'- and 3'-hydroxyl groups, as in compound 27, resulted in a 3-fold loss of potency at A_1 receptors (vs 26) and an apparent slight gain in affinity at A_{2a} receptors.

The 2'-methoxy derivative of the A_1 -selective agonist N^6 -cyclohexyladenosine (CHA) has been reported by Wagner et al. ³³ to have substantial *in vivo* activity, perhaps as a prodrug of CHA. We have evaluated methoxy derivatives of adenosine at the three subtypes and found the 3'-derivative **28a** to be nonselective and of very weak affinity and the 2'-derivative **28b** to be inactive. The inclusion of methyl groups in place of hydrogen in the ribose ring was examined in compounds **29a,b.** The 3'-methyl analogue **29a** bound weakly with A_1 selectivity, while the 4'-methyl analogue **29b** was virtually inactive.

Limited modification of the 5'-position of adenosine is tolerated at adenosine receptors. NECA, **31**, has long been known as a highly potent, nonselective agonist. A cytotoxic aminosulfonate derivative **30**³⁴ was much less potent than NECA, with K_i values in the 1–10 μ M range. 1-Deaza-NECA, **31**, as reported previously, has substantial activity at A₁ receptors, and at A_{2a} and A₃ receptors, the potencies vs those of NECA are diminished by factors of 56- and 6-fold. Thus, at A_{2a} and A₃ receptors, the 1-deaza substitution is tolerated better in the 2-chloro series (cf. compounds **1** and **2**), while at A₁ receptors, the 1-deaza modification is tolerated better in the uronamide series. The addition of the 2-hexynyl group to NECA, resulting in the A_{2a} selective agonist compound **33** (HE-NECA), previously studied in platelets and on the coronary artery, hand and have a potency. Thus, the order of selectivity of HE-NECA (with K_i values in nM) is A_{2a} (2.2) > A₃ (25.6) > A₁ (130).

Numerous modifications of the N^6 -position of adenosine have been introduced and shown to result generally, but not exclusively, in A_1 selectivity. Table 1b shows a comparison of affinities of a variety of N^6 -substituted analogues. 6-Hydrazinopurine riboside, **34**, had K_i values in the 10^{-5} M range and was nearly nonselective for $A_1/A_{2a}/A_3$ receptors. 1-Deaza-6-(hydroxylamino)-purine riboside, **35**, also bound weakly but was 1 order of magnitude selective for A_1 and A_{2a} vs A_3 receptors. The affinity of adenosine, itself, for comparison with these compounds is difficult to evaluate, due to the presence of adenosine deaminase in the medium.

At A_3 receptors, N^6 -benzyl substituents, as in **36**, have been shown to be favored. Several other known N^6 -arylmethylene analogues were studied. Metrifudil, **37**, a potent hypotensive agent, which had entered human trials in the early 1970's, 37 was found to be 2.5-fold selective for rat A_{2a} vs A_1 receptors and 15-fold selective for rat A_{2a} vs A_3 receptors. The affinity of **37** was enhanced 12-fold and diminished 3-fold at A_{2a} and A_3 receptors, respectively, by the presence of the 2-methyl group on the benzyl ring. (–)-Kinetin riboside, 45 **38**, was also slightly selective for A_{2a} receptors, although 5-fold less potent than metrifudil. An N^6 -bicyclic methylene analogue, **39**, was slightly selective for A_1 receptors.

 N^6 -Benzyl-NECA was the first A_3 selective agonist identified, 9 although it was only 14-fold selective verses either A_1 or A_{2a} receptors. The corresponding N-methyl analogue **40** had enhanced potency and selectivity. 8 A 4'-methyl analogue, **41**, displayed even greater selectivity, although it was 38-fold less potent than **40** at A_3 receptors. Compound **41** was 100- and 89-fold selective for A_3 vs A_1 and A_{2a} receptors, respectively. Curiously, the affinity of **41** is in contrast to the inactivity of the simple 4'-methyladenosine derivative **29b.** The combination of the 5'-N-methyluronamide group with the N^9 -furfuryl group of kinetin riboside resulted in an A_3 -selective compound, **42**, of micromolar affinity.

A selective A_3 agonist that has been studied *in vivo* is IB-MECA, **43**. 10,11 The carbocyclic analogue of IB-MECA, **44**, was weakly binding and more potent at A_1 and A_3 vs A_{2a} receptors. IB-MECA, **43**, was 18 000-fold more potent than this carbocyclic analogue at A_3 receptors.

Since many of the adenosine derivatives diverge greatly in structure from adenosine itself, it was not to be assumed that all of the compounds found to bind to the receptors were agonists. Previously, removal of the 2' and 3'-hydroxyl groups of N⁶-substituted adenosine derivatives was shown to result in partial agonist or antagonist properties. ^{15,38} Therefore we tested selected analogues for A₁ agonist efficacy using a straight forward binding method. GTP shifts in the displacement curves for agonist verses antagonist have been shown to be indicative of agonist.³⁸ Thus, we examined the ability of selected analogues to displace the antagonist radioligand [3H]CPX and the degree of shift of the displacement curve in the presence of 1 mM GTP, and the results are given in Table 3. For agonists a typical shift in the K_i value is > 2-fold. Full agonists, such as (R)-PIA and CPA, under the same conditions give shifts of 5.5 and 6.0, respectively. For pure antagonists, no shift or only a very small shift is expected. For example, the value for the A₁ adenosine antagonist 9-methyladenine ¹⁴ is 1.2. Compound 22 appears to be in the antagonist range, which is consistent with its highly unnatural carbohydrate moiety. Compounds 21 and 25 are predicted to be partial agonists at A₁ receptors. The 2'-deoxy 2'-fluoro analogue, compound 23, is likely a full agonist.

Compound **41**, which was A_3 selective, was tested in a functional assay at rat A_3 receptors. Compound **41** inhibited adenylate cyclase (Figure 1), using membranes from CHO cells stably transfected with rat A_3 receptors. We previously demonstrated that compounds with high affinity in binding were very active in this assay of A_3 -mediated inhibition of adenylate cyclase. ³⁹ Compound **41** appeared to be a full agonist, with an inhibition of forskolinstimulated adenylate cyclase of 32.7% \pm 3.2% at 10^{-4} M and an IC₅₀ value of 10 μ M. (based on a maximal inhibition of 40%). Thus it was less potent than NECA, **31**, which had an IC₅₀ value of 5.6 μ M, but was more selective for A_3 receptors.

Discussion

The results of this study imply the existence of receptor binding sites for adenosine with very strict structural requirements. 1-Deaza modification of adenosine derivatives is well tolerated at A_1 , A_{2a} , and A_3 receptors. The marked difference in affinity between 2-chloroand 2-fluoroadenosine at rat A_3 receptor suggests preference for hydrophobic interaction near the 2-position of the purine ring. Substitution at the 8-position of adenosine resulted in agonists having decreased affinity for all the receptor subtypes.

Carbocyclic nucleosides were in general weakly A_{2a} selective ligands and showed poor affinity for A_3 receptors. Therefore it can be assumed that the 6'-oxygen of the ribose moiety is beneficial for binding to A_1 and A_3 receptors. Interestingly deletion of the 5'-methylene group of carbocyclic nucleosides (5'-noraristeromycin derivatives) resulted in

enhanced affinity at A_1 and A_{2a} receptors. However, substitution at the 2-position of the purine ring of carbocyclic nucleosides did not enhance their affinity at A_{2a} receptors.

Replacement of the 6'-oxygen by sulfur was well tolerated at all the adenosine receptors. Adenine- β -D-arabinofuranoside, **20**, was weakly potent at all the receptor subtypes. ⁹ Curiously, the 2'-deoxyxylose modification combined with the 6'-thio modification resulted in enhanced binding at A_1 and A_{2a} receptors and a moderate affinity for A_3 receptors. In general 6'-thio and carbocyclic modifications of agonists were more suitable for increasing A_{2a} selectivity.

Various 2'-deoxy- and 2',3'-dideoxyadenosine analogues were inactive in binding at rat A₃ receptors, but they showed considerable binding affinity at A₁ and A_{2a} receptors. Compounds **21** and **25** were putative partial agonists. 2-Chloro-2'-deoxy-1-deazaadenosine, **26**, was active, possibly as a partial agonist at A₁ receptors only. Recently Sipe et al.⁴⁰ reported that therapeutic use of 2-chloro-2'-deoxyadenosine, **25**, an antileukemic drug, slowed the progression of multiple sclerosis.

 β -L-Adenosine, **17**, bounds appreciably A_1 receptors only. However, β -L-5′-noraristeromycin, **18**, was an A_{2a} selective ligand. Surprisingly, when 6′-thio and 2′-deoxyxylo modifications were applied to the β -L-nucleoside enantiomer, the resultant nucleoside, **22**, behaved as an antagonist at A_1 receptors.

The 2-chloro 1-deaza modification was well tolerated at A_{2a} and A_3 receptors. Combination of the 1-deaza modification with a 5'-uronamide group leads to A_1 selectivity. Replacement of the 6-amino group by hydrazine or hydroxylamine was tolerated. Substitution at N^6 by benzyl, furfuryl, and benzopyryl groups was well tolerated at A_1 , A_{2a} , and A_3 receptors. N^6 -Substitution modification combined with 5'-uronamide derivatives increased A_3 selectivity. Substitution of 4'-hydrogen by a methyl group (compound 41) maintained agonist activity at A_3 receptors and selectivity. This methyl group is designed to diminish metabolic hydrolysis of the amide group *in vivo* to provide a longer biological half-life. The 5'-uronamide N^6 -benzyl-modified carbocyclic nucleoside 44 displaced binding at A_1 and A_3 receptors. It is to be noted that the inactivity of a singly modified derivative of adenosine, e.g., 29b, does not preclude activity in multiple modified versions of the same, e.g., 41.

Most of the compounds in this study are not substrates for adenosine deaminase. Those analogues having the N^6 -alkyl, 5'-carboxamido, 2-chloro, 3- and 7-deaza, and 8-position modifications, and the carbocyclic "nor" analogues (e.g., **9**, **10a**, **12c**, and **16**), ^{24a} are expected to be stable to adenosine deaminase. It is possible that some of the compounds (**20**, **24**, **28**, and **29**) may be substrates for adenosine deaminase and that any residual deaminase present during the binding assay may raise the observed K_i value. Compound **7** is reported to be an adenosine deaminase substrate. ⁵¹ Compound **35** is an inhibitor of adenosine deaminase in the micromolar range. ⁴⁸

Conclusions

The most significant new compound, N^6 -benzyl-4'-methyladenosine-5'-(N-methyluronamide), **41**, was identified as an A_3 selective agonist, and it displayed a K_i value of 604 nM at A_3 receptors and was 103- and 88-fold selective vs A_1 and A_{2a} receptors, respectively. Compounds **1,3**, and **25** were A_1 selective. Compounds **17,35**, and **39** were somewhat selective for A_1 receptors. Compounds **4**, **5**, **22**, **37**, **38**, and **39** were identified as slightly A_{2a} selective ligands. The moderately A_{2a} selective agonists were **9**, **11**, **18**, **19**, and **33**. On the basis of intermediate GTP shifts in binding versus an antagonist radioligand, 2-chloro-2'-deoxyadenosine, **25**, and 2-chloroadenine-9-(β -D-6'-thioarabinoside), **21**, are

putative partial agonists at A_1 receptors, with K_i values of 7.4 and 5.4 μ M, respectively. Compound 22 was identified as an A_1 antagonist from this search for new leads for ligand selectivity at adenosine receptors. We are synthesizing derivatives of 22 to enhance its potency as antagonists at adenosine receptors subtypes.

Although the corresponding simple 4'-methyladenosine derivative **29b** was inactive at adenosine receptors, compound **41**, containing two other modifications as well, was an A_3 selective, full agonist. Thus, this study emphasizes that inactivity or low binding affinity of an adenosine derivative does not preclude activity in optimally modified derivatives of the same ligand.

Experimental Section

All chemicals were purchased from Aldrich (Milwaukee, WI) unless otherwise noted. Compounds **28b** and **34** were the gift of the Drug Synthesis & Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment, NCI. Compounds **1**, **7**, **31**, and **38** were purchased from Sigma Chemicals, St. Louis, MO. Cylinders of ammonia and methylamine were obtained from Union Carbide and Matheson, respectively. Anhydrous methyl alcohol and *tert*-butyl alcohol were used from freshly opened bottles as received. Column chromatography was carried out with silica gel 60 from EM Science (230–400 mesh). ¹H and ¹³C NMR spectra were recorded in the solvent and field strength noted. Chemical shifts are reported relative to the solvent standard. Elemental analyses were performed by Midwest Microlab, Indianapolis, IN, and M-H-W Laboratories, Phoenix, AZ.

(\pm) - $(1\alpha,2\beta)$ -2-(2,6-Diamino-9*H*-purin-9-yl)cyclopentan-1-ol (12a)

Compound **68** (220 mg, 0.87 mmol) in MeOH (30 mL) saturated with anhydrous NH₃ was heated in a sealed cylinder at 100 °C for 12 h. The solvent was removed under reduced pressure and the residue purified by column chromatography (CH₂Cl₂:MeOH, 9:1) to give **12a** as white crystals following recrystallization from MeOH (140 mg, 69.7%): mp 214–215 °C; 1 H NMR (DMSO- d_{6}) δ 1.5–2.2 (m, 6 H, 3 × CH₂ of cyclopentyl), 4.20 (m, 2 H, H-1 and H-2 of cyclopentyl), 5.79 (s, 2 H, NH₂), 6.69 (s, 2 H, NH₂), 7.74 (s, 1 H, H-8 of purine); 13 C NMR (DMSO- d_{6}) δ 19.90, 28.97, 31.99, 62.15, 74.93, 113.57, 136.30, 151.88, 156.04, 159.77.

(1S,2R,3S,4R)-4-[6-Amino-2-[(phenylethyl)amino]-9H-purin-9-yl]cyclopentane-1,2,3-triol (12c)

To a suspension of **48** (300 mg, 1.05 mmol) in absolute EtOH (10 mL) was added phenylethylamine (300 mg, 2.45 mmol). This mixture was heated at 90 °C for 3 days. The solvent was removed by rotary evaporation, and the residue was subjected to column chromatography on silica gel (eluent CH₂Cl₂–MeOH) to give **12c** (272 mg, 70%) as a yellow solid: mp 200 °C dec; ¹H NMR (DMSO- d_6) δ 1.77–1.90 (m, 1 H, H-5′), 2.50–2.60 (m, 1 H, H-5′), 2.8 (m, 4 H, 2 × CH₂), 3.75 (m, 1 H, H-2′), 3.89 (m, 1 H, H-1′), 4.40–4.52 (m, 1 H, H-3′), 4.62–4.81 (m, 1 H, H-4′), 4.87 (d, 1 H, J= 3.6 Hz, OH), 5.01 (d, 1 H, J= 6.6 Hz, OH), 5.36 (d, 1 H, J= 4.8 Hz, OH), 7.22 (s, 2 H, NH₂), 7.48 (m, 5 H, Ph), 8.48 (s, 1 H, H-8).

(±)-1 α ,2 β ,3 β ,5 β)-3-[2-[[4-(1-Butyl)phenyl]amino]-4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-5-(hydroxymethyl)-1,2-cyclopentanediol (15b)

Into an ice-cooled solution of **64** (500 mg, 1.16 mmol) in dry MeOH (50 mL) was bubbled anydrous NH₃ until a saturated solution was obtained. The mixture was transferred to a sealed tube and heated at 125 °C for 55 h. After cooling to 0 °C, the sealed tube was opened and the volatiles were removed by evaporation *in vauo*. The residual solid was

chromatographed on silica gel (CH₂-Cl₂–MeOH, 9:1). The product-containing fractions were evaporated to dryness, and the residue was rechromatographed on 5 g of Norit-A (CH₂Cl₂–MeOH, 6:4) to give pure **15b** (454 mg, 95%): mp 210–213 °C; ¹H NMR (DMSO- d_6) δ 0.89 (t, 3 H, Me), 1.42 (m, 5 H, 2 × CH₂ and H-4′), 1.9 (m, 2 H, H-4′ and H-5′), 2.5 (m, 2 H, CH₂), 3.0–4.1 (m, 7 H, *CH*₂OH, H-1′, H-2′, H-3′, and 2 × OH), 5.0 (m, 1 H, OH), 6.4 (d, J = 3.8 Hz, 1 H, H-7), 7.0 (d, J = 8.5 Hz, 2 H, ArH). 7.4 (br, 3 H, H-8 and NH₂), 7.7 (d, J = 8.5 Hz, 2 H, ArH), 8.8 (br, 1 H, NH); ¹³C NMR (DMSO- d_6) δ 13.76, 21.67, 30.06, 33.23, 34.13, 46.38, 55.15, 63.38, 77.14, 78.07, 100.38, 101.09, 118.43, 120.59, 128.56, 135.65, 136.89, 147.41, 148.82, 158.35.

N⁶-(Benzodioxanylmethy)adenosine Hemihydrate (39)

6-Chloropurine riboside (200 mg, 0.70 mmol) was refluxed in 10 mL of ethanol with 162 mg (0.77 mmol) of racemic benzdioxan-2-methylamine and 2 g (2.1 mmol) of triethylamine solution (5.3 g of triethylamine in 50 g of ethanol) for 18 h. After 48 h at -20 °C, a white crystalline product was formed that was collected and dried. Further workup afforded a second crop of the product: total yield 180 mg (62%); mp 176–178 °C; MS (CI) MH⁺ = 416.

1-[6-(Benzylamino)-9*H*-purin-9-yl]-1-deoxy-*N*,4-dimethyl-β-D-ribofuranosiduronamide (41)

The diacetyl nucleoside **52** (195 mg, 0.474 mmol) was selectively deacylated by treatment with a methanolic solution of NH₃ at 0 °C for 10 min. The solution was evaporated to dryness, and to the residue was added a 1:1 solution of *t*-BuOH and benzylamine (4 mL). This solution was heated at 70 °C for 16 h and concentrated under reduced pressure (0.1 Torr, 40 °C). Chromatography of the residue on silica gel (gradient 30:1–10:1 CH₂Cl₂:MeOH) gave 159 mg (84%) of *N*-benzyladenine nucleoside **41** as a white solid: [a]²³_D–25.7° (*c* 1.02, CH₃OH); ¹H NMR (500 MHz, CD₃OD, prior H–D exchange) δ 8.29 (s, 1 H), 8.13 (s, 1 H), 7.35 (d, 2 H, J = 7.0 Hz), 7.28 (t, 2 H, J = 7.5 Hz), 7.21 (t, 1 H, J = 7.5 Hz), 5.97 (d, 1 H, J = 8.5 Hz), 4.83 (dd, 1H, J = 8.5, 5.0 Hz), 4.78 (br s, 2 H), 4.30 (d, 1 H, J = 5.0 Hz), 2.82 (s, 3 H), 1.50 (s, 3 H); ¹³C NMR (125 MHz, CD₃OD) δ 174.98, 154.73, 152.48, 148.33, 140.77, 138.78, 128.13, 127.10, 126.81, 120.10, 88.16, 87.74, 73.75, 71.75, 43.62, 24.90, 18.79.

1-[6-(Furfurylamino)-9H-purin-9-yl]-1-deoxy-N-methyl-β-D-ribofuranosiduronamide (42)

To a solution of 2', 3'-isopropylidene-1-(6-chloro-9H-purin-9-yl)-1-deoxy-N-methyl- β -Dribofuranosiduronamide⁸ (50 mg, 0.16 mmol) in absolute EtOH (5 mL) was added furfurylamine (20 mg, 0.21 mmol). This mixture was heated at 90 °C for 20 h. After cooling to room temperature, solvent was removed by rotary evaporation and the residue was dissolved in 0.5 N HCl and heated at 60 °C for 1 h. After cooling to 0 °C in an ice bath, the reaction mixture was neutralized with concentrated NH₄OH and evaporated to dryness. The residue was purified by preparative thin-layer chromatography on silica gel to give **42** (21 mg, 40%) as white solid: 1 H NMR (DMSO- d_6) δ 3.32 (d, J= 4.3 Hz, 3 H, Me), 4.12 (m, 1 H, H-3'), 4.33 (s, 1 H, H-4'), 4.60 (dd, J= 4.6, J= 4.3 Hz, 1 H, H-2'), 4.70 (br s, 2 H, N⁶- CH_2), 5.53 (d, J= 6.4 Hz, 1 H, OH-2'), 5.56 (d, J= 7.4 Hz, 1 H, H-1'), 5.71 (d, J= 4.1 Hz, 1 H, OH-3'), 5.60 (d, J= 7.4 Hz, 1 H, H-1'), 7.3 (m, 3 H), 8.42 (s, 1 H, H-8), 8.56 (br s, 1 H, H-N^e), 8.55 (br s, 1 H, NH-Me).

(±)-9-[2α,3α-Dihydroxy-4 β -(*N*-methylcarbamoyl)cyclopent-1 β -yl)]- N^6 -(3-iodobenzyl)adenine (44)

To a solution of **57** (100 mg, 0.32 mmol) in absolute EtOH (10 mL) was added 3-iodobenzylamine hydrochloride (90 mg, 0.34 mmol), and the resulting mixture was heated at 90 °C for 24 h, under a nitrogen atmosphere. The solvent was removed by evaporation *in vacuo*, and the residue was purified by column chromatography on silica gel (eluent

CH₂Cl₂–MeOH, 10:0.5) to give **44** (140 mg, 85%) as colorless foam: 1 H NMR (DMSO- d_{6}) δ 2.71 (s, 2 H, CH₂), 3.31 (m, 1 H, H-1′), 3.42 (d, J=4.3 Hz, 3 H, Me), 4.32 (m, 1 H, H-3′), 4.35 (s, 1 H, H-4′), 4.70 (s, 2 H, CH_{2} -Ph), 4.74 (dd, J=4.0, J=4.3 Hz, 1 H, H-2′), 5.45 (d, J=6.4 Hz, 1 H, OH-2′), 5.60 (d, J=4.1 Hz, 1 H, OH-3′), 5.60 (d, J=7.4 Hz, 1 H, H-1′), 7.13 (t, J=7.1 Hz, 1 H), 7.40 (d, J=7.7 Hz, 1 H), 7.60 (d, J=7.6 Hz, 1 H), 8.21 (s, 1 H, H-8), 8.50 (br s, 1 HN⁶), 8.60 (br s, 1 H, N*H*-Me).

(1R,4S)-4-(2,6-Dichloro-9H-purin-9-yl)cyclopent-2-en-1-ol (46)

To a solution of 2,6-dichloropurine (2 g, 10.64 mmol) in dry DMSO (25 mL) was added sodium hydride (60% suspension in mineral oil, 0.42 g, 10.64 mmol). The reaction mixture was stirred at the room temperature for 30 min followed by the addition of tetrakis(triphenylphosphine)-palladium (0.5 g, 0.22 mmol), triphenylphosphine (0.25 g, 0.95 mmol), and a solution of (+)- 45^{20} (1.66 g, 11.70 mmol) in dry THF (25 mL). This mixture was stirred at 50 °C for 20 h. The volatiles were removed by rotary evaporation *in vacuo* at 50 °C. The residue was slurried in CH₂Cl₂ (50 mL) and filtered to remove insoluble solids. The filtrate that resulted was washed with brine (2 × 50 mL), dried (MgSO₄), and evaporated to dryness. The residual oil was purified by flash chromatography on silica gel by eluting first with AcOEt to remove the nonpolar impurities and then with AcOEt–MeOH (9:1). The product containing fractions were evaporated to dryness to give 46 (3.55 g, 89%) as a colorless foam: 1 H NMR (DMSO- 1 G) 1 G1.62–2.7 (m, 2 H, H-5'), 3.26 (m, 3 H, OH), 3.65 (m, 1 H, H-1'), 4.58 (m, 3 H, H-2', H-3', H-4'), 8.34 (m, 1 H, H-8).

(1S,2R,3S,4R)-4-(6-Amino-2-chloro-9H-purin-9-yl)cyclopentane-1,2,3-triol (48)]

To a solution of **46** (1 g, 3.70 mmol) in THF-H₂O (10:1, 50 mL) was added a 60% aqueous solution of *N*-methylmorpholine *N*-oxide (1.2 mL, 1.14 mmol) and then osmium tetraoxide (30 mg). The reaction mixture was stirred at room temperature for 24 h. The solvent was removed by rotary evaporation, and the residue was coevaporated with EtOH (3 × 50 mL) to give a gummy material. This residue was dissolved in MeOH presaturated with anhydrous ammonia (50 mL) and stirred in a sealed tube at room temperature for 5 days. Volatiles were removed by rotary evaporation, and the residue was subjected to column chromatography on silica gel (eluent MeOH–CH₂Cl₂, 9:1) to give **48** (800 mg, 80%) as a white solid: mp 180 °C dec; ¹H NMR (DMSO- d_6) δ 1.77–190 (m, 1 H, H-5′), 2.50 (m, 1 H, H-5′) 3.75 (m, 1 H, H-2′), 3.89 (m, 1 H, H-1′), 4.40–4.52 (m, 1 H, H-3′), 4.62–4.81 (m, 1 H, H-4′), 4.87 (d, 1 H, J = 3.6 Hz, OH), 5.01 (d, 1 H, J = 6.6 Hz, OH), 5.36 (d, 1 H, J = 4.8 Hz, OH), 7.22 (s, 2 H, NH₂), 8.11 (s, 1 H, H-8).

Methyl 2,3-O-Isopropylidene-N,4-dimethyl-β-D-ribofuranosiduronamide (50)

A solution of methyl ester **49**²¹ (502 mg, 2.04 mmol) in MeOH (30 mL) was saturated with gaseous methylamine and stirred until TLC (2:1 hexane: EtOAc) showed the reaction was complete. The solution was concentrated and the residue chromatographed on silica gel (1.5:1 hexane:EtOAc) to give 502 mg (100%) of **50** as a clear oil: $[\alpha]^{23}_{D}$ –45.0° (c 1.05, CH₂Cl₂); ¹H NMR (300 MHz, CDCl₃) δ 6.56 (br s, 1 H), 5.10 (d, 1 H, J = 5.9 Hz), 4.93 (s, 1 H), 4.51 (d, 1 H, J = 5.9 Hz), 3.39 (s, 3 H), 2.79 (d, 3 H, J = 5.0 Hz), 1.47 (s, 3 H), 1.44 (s, 3 H), 1.30 (s, 3 H); ¹³C NMR (75 MHz, CDCl₃) δ 174.55, 112.53, 110.25, 89.33, 85.15, 82.35, 55.96, 26.16, 25.98, 24.76, 20.96.

Methyl 2,3-O-Diacetyl-N,4-dimethyl- β -D-ribofuranosiduronamide (51)

To a solution of acetonide **50** (502 mg, 2.04 mmol) in MeOH (60 mL) was added concentrated HCl (0.1 mL). The solution was stirred for 18 h and then concentrated under reduced pressure. The residue was chromatographed on silica gel (gradient EtOAc–30% MeOH in EtOAc) to give 105 mg (21%) of starting acetonide and 310 mg of diols as a

mixture of glycosides which were acetylated with Ac₂O (0.48 mL) and pyridine (0.85 mL) in CH₂Cl₂ (30 mL) containing a catalytic amount of DMAP. Toluene (10 mL) was added, and the solution was concentrated to dryness. The residue was chromatographed on silica gel (1:1 hexane:EtOAc) to give 380 mg (64%) of *β*-**51** and 40 mg (7%) of α-**51** (81% and 8.5% yields, respectively, based on recovered acetonide). *β*-**51**: oil; $[\alpha]^{23}_D$ –27.5° (*c* 1.2, CH₂Cl₂); 1 H NMR (300 MHz, CDCl₃) δ 6.77 (br s, 1 H), 5.54 (d, 1 H, J = 4.8 Hz), 5.19 (dd, 1 H, J = 3.2, 4.8 Hz), 5.01 (d, 1 H, J = 3.2 Hz), 3.48 (s, 3 H), 2.82 (d, 3 H, J = 5.0 Hz), 2.10 (s, 3 H), 2.05 (s, 3 H), 1.46 (s, 3 H); 13 C NMR (75 MHz, CDCl₃) δ 173.26, 169.19 (2), 106.54, 85.69, 74.71, 73.75, 56.87, 26.11, 20.56 (2), 20.45. Anal. Calcd for C₁₂H₁₉NO₇: C, 49.82; H, 6.62. Found: C, 49.75; H, 6.52. α-**51**: mp 112–113 °C (CH₂Cl₂/hexane); 1 H NMR (300 MHz, CDCl₃) δ 6.71 (br s, 1 H), 5.64 (d, 1 H, J = 6.3 Hz), 5.12 (d, 1 H, J = 4.8 Hz), 4.94 (dd, 1 H, J = 6.3, 4.8 Hz), 3.42 (s, 3 H), 2.81 (d, 3 H, J = 5.0 Hz), 2.16 (s, 3 H), 2.08 (s, 3 H), 1.48 (s, 3 H); 13 C NMR (75 MHz, CDCl₃) δ 172.92, 169.81, 169.58, 101.35, 85.59, 72.08, 70.78, 55.83, 26.08, 21.14, 20.65, 20.45.

2,3-*O*-Diacetyl-1-(6-chloro-9*H*-purin-9-yl)-1-deoxy-*N*,4-dimethyl- β -D-ribofuranosiduronamide (52)

A suspension of 6-chloropurine (590 mg, 3.82 mmol) in hexamethyldisilazane (6 mL) was heated to 100 °C until dissolution was complete, ca. 1 h. Toluene (2 mL) was added, and the solution was concentrated under an inert atmosphere. To remove final traces of HMDS, toluene $(2 \times 4 \text{ mL})$ was again added and the solution was concentrated in a similar manner. To the silylated 6-chloropurine in dry CH₃CN (3 mL) was added 307 mg (1.05 mmol) of β-51 (dried by azeotropic distillation with toluene under reduced pressure) in dry CH₃CN (5 mL) and trimethylsilyl trifluoromethanesulfonate (0.75 mL). This solution was heated to reflux for 12 h. The two initial nucleoside products detected by TLC gave way to a single thermodynamic product during this time. The reaction mixture was cooled, the reaction quenched by the addition of saturated aqueous NaHCO₃ (1 mL), and the mixture partitioned between CH₂-Cl₂ (40 mL) and H₂O (10 mL). The aqueous layer was extracted with CH₂Cl₂ (2 × 40 mL). The combined organics were dried (MgSO₄), filtered, and concentrated under reduced pressure. Column chromatography on silica gel (1:2 CH₂Cl₂: EtOAc) gave 270 mg (63%) of 6-Cl-purine nucleoside **52** as a faint yellow foam: $[\alpha]^{23}$ _D 2.48° (c 1.45, CH₂Cl₂); ¹H NMR (300 MHz, CDCl₃) δ 8.68 (s, 1 H), 8.27 (s, 1 H), 7.61 (br q, 1 H, J = 4.9 Hz), 6.15 (d, 1 H, J = 7.5 Hz), 6.00 (dd, 1 H, J = 7.5, 5.0 Hz), 5.82 (d, 1 H, J = 5.0 Hz), 2.77 (d, 3 H, J= 4.9 Hz), 2.13 (s, 3 H), 1.88 (s, 3 H), 1.49 (s, 3 H); ¹³C NMR (75 MHz, CDCl₃) δ 171.13, 168.78 (2), 151.80, 151.56, 150.96, 144.67, 133.39, 86.80, 86.07, 73.03, 71.15, 25.99, 20.20, 19.96, 19.75.

(±)-9-[2 α ,3 α -Dihydroxy-4 β -(N-methylcarbamoyl)cyclopent-1 β -yl)]-6-chloropurine (57)

To a solution of compound **54** (1 g, 7.04 mmol, prepared according to the procedure reported by Cermak and Vince⁴⁷) in dry MeOH (20 mL) was bubbled anhydrous methylamine for 10 min. The resulting solution was heated at 90 °C in a sealed tube for 20 h. After cooling to room temperature, solvent was removed by rotary evaporation *in vacuo* and the residue was used in the next step without further characterization. To this residue were added 5-amino-4,6-dichloropyrimidine (1.00 g, 6.13 mmol), triethylamine (2 mL), and *n*-BuOH (20 mL). The resulting mixture was heated at 100 °C, under an N₂ atmosphere, for 24 h. Volatiles were evaporated *in vacuo*, and the residue was dissolved in methyl diethoxyacetate (10 mL). This mixture was heated at 100 °C for 2 h and then evaporated to dryness. The residue was dissolved in 1 N HCl (10 mL) and stirred at room temperature for 3 h. The ice-cold reaction mixture was neutralized with concentrated NH₄OH and evaporated to dryness. The residue was subjected to column chromatography on silica gel (eluent CH₂Cl₂–MeOH, 9.5:0.5) to give **57** (1.3 g, 59% yield based upon **54**) as a yellow foam: ¹H NMR (DMSO- d_6) δ 2.75 (s, 2 H, CH₂), 3.33 (m, 1 H, H-1′), 3.40 (d, J= 4.3 Hz,

3 H, Me), 4.22 (m, 1 H, H-3'), 4.33 (s, 1 H, H-4'), 4.75 (dd, J = 4.0, J = 4.3 Hz, 1 H, H-2'), 5.45 (d, J = 6.4 Hz, 1 H, OH-2'), 5.60 (d, J = 4.1 Hz, 1 H, OH-3'), 5.60 (d, J = 7.4 Hz, 1 H, H-1'), 8.21 (s, 1 H, H-8), 8.50 (br s, 2 H, HN⁶), 8.60 (br s, 1 H, N*H*-Me).

5-Allyl-2-[[4-(1-butyl)phenyl]amino]-4,6-dihydroxypyrimidine (58)

N-[4-(1-Butyl)phenyl]guanidine nitrate⁵⁶ (16 g, 62.99 mmol) was added to cold NaOEt in EtOH (250 mL prepared by dissolving 25 g of Na in 250 mL of absolute EtOH). This mixture was stirred at 5 °C for 10 min before diethyl allylmalonate (12.59 g, 62.95 mmol; Aldrich Chemical Co.) was added. The reaction mixture was then refluxed for 3 h. Concentrated HCl (40 mL) was added to the cold reaction mixture, which was allowed to stand for several hours. The crude product and inorganic salts precipitated. After filtration and washing the crude mixture with water and recrystallization of this material using EtOH, 12.5 g (66%) of pure **58** was obtained: mp 211–212 °C; ¹H NMR (DMSO- d_6) δ 0.81 (t, 3 H, CH₃), 1.39 (m, 4 H, 2 × CH₂), 2.44 (t, 2 H, CH₂), 2.90 (d of t, 2 H, CH₂), 3.03 (br, 1 H, OH), 4.86 (m, 2 H, CH₂), 5.61 (m, 1 H, CH), 7.09 (d, 2 H of C₆H₅), 7.62 (d, 2 H of C₆H₅), 8.57 (s, 1 H, side chain NH), 10.50 (br, 1 H, ring OH/NH); ¹³C NMR (DMSO- d_6) δ 13.77, 21.73, 26.39, 33.32, 34.25, 90.75, 113.66, 119.89, 128.51, 136.20, 136.80, 149.58, 165.08.

5-Allyl-2-[[4-(1-butyl)phenyl]amino]-4,6-dichloropyridimidine (60)

To a suspension of dried 58 (10 g, 33.44 mmol) in dry acetonitrile (150 mL) was added tetraethylammonium chloride (dried over P₂O₅) (2 g, 17.09 mmol) followed by N,Ndiethylaniline (2.5 mL) and phosphorus oxychloride (30 mL). The reaction mixture was kept in an oil bath preheated at 70 °C for 2 h. An additional amount of phosphorus oxychloride (20 mL), containing N,N-diethylaniline (1.5 mL), was added, and the temperature was raised to 100 °C. After 2 h, the volatiles were evaporated under reduced pressure and the residue was dissolved in CHCl₃ (100 mL). The organic solution was added to ice H₂O, and the layers were separated. The aqueous layer was extracted with CHCl₃ (3×50 mL), and the combined organic extracts were washed with saturated aqueous NaHCO₃ solution (2 × 50 mL) and then H₂O (2 × 50 mL). The CHCl₃ solution was dried over MgSO₄ and filtered, and the filtrates were evaporated on a rotary evaporator to yield crude 60. Recrystallization of this material using MeOH afforded 7.72 g (69%) of pure **60**: mp 70–72 °C; ¹H NMR $(CDCl_3) \delta 0.89 (t, 3 H, CH_2), 1.25 (m, 4 H, 2 \times H_2), 2.48 (m, 2 H, CH_2), 3.97 (m, 2 H,$ CH₂), 5.03 (m, 2 H, CH₂), 6.00 (m, 1 H, CH₂), 7.36 (m, 5 H, C₆H₅ and NH); ¹³C NMR $(CDCl_3)$ δ 13.89, 22.23, 33.23, 33.61, 34.96, 116.71, 119.58, 128.79, 132.42, 135.67, 138.22, 156.91, 161.78.

[2-[[4-(1-Butyl)phenyl]amino]-4,6-dichloropyrimidin-5-yl]acetaldehyde (61)

To a suspension of **60** (37.12 g, 110.81 mmol) in MeOH (300 mL), acetone (200 mL), and $\rm H_2O$ (200 mL) were added $\rm OsO_4$ (230 mg) and $\rm NaIO_4$ (94.8 g, 443.21 mmol). After mechanically stirring for 48 h, the reaction mixture was evaporated to remove the organic solvent. The suspension was diluted with $\rm H_2O$ (500 mL) and extracted several times with EtOAc. The EtOAc layer was separated, dried over MgSO₄, and evaporated to dryness. The crude product was recrystallized from a small amount of MeOH to give **61** (29.83 g, 79%) as white needles: $^1\rm H$ NMR (DMSO- d_6) δ 0.91 (t, 3 H, CH₃), 1.40 (m, 4 H, 2 × CH₂), 1.99 (t, 2 H, CH₂), 3.90 (s, 2 H, *CH*₂CHO), 7.16 (d, *J* = 8.5 Hz, 2 H, ArH), 7.4 (d, *J* = 8.5 Hz, 2 H, ArH), 9.7 (s, 1 H, NH), 10.25 (s, 1 H, *CHO*); $^{13}\rm C$ NMR (DMSO- d_6) δ 13.87, 21.71, 33.20, 34.24, 43.58, 112.65, 119.66, 128.38, 136.36, 137.01, 158.81, 161.37, 197.79.

2-[[4-(1-Butyl)phenyl]amino]-4,6-dichloro-5-(2,2-dimethoxyethyl)pyrimidine (62)

To a solution of 61 (29.25 g, 86.79 mmol) in dry MeOH (250 mL) was added pyridinium p-toluensulfonate (2.18 g, 8.67 mmol) and NH₄Cl (460 mg, 8.68 mmol, freshly dried over

 P_2O_5), and this solution was refluxed for 4 h. After cooling to room temperature, the reaction mixture was treated with Norit-A and filtered through a pad of Celite, and the filtrate was evaporated to dryness. The residue was dissolved in AcOEt–hexane (2:8) and filtered through a plug of Florisil (150 g). Removal of the solvent and chromatography on Florisil (AcOEt–hexane, 2:8) gave **62** (29.71 g, 89%) as a yellow oil, which crystallized slowly at room temperature and was recrystallized from hexane to give pure **62** as colorless needles: mp 52–55 °C; 1 H NMR (CDCl₃) δ 0.93 (t, 3 H, Me), 1.3 (m, 4 H, 2 × CH₂), 2.5 (t, 2 H, CH₂), 3.0 (d, 2 H, CH₂), 3.3 (s, 6 H, OMe), 4.5 (t, 1 H, (MeO)₂C*H*), 7.1 (d, *J* = 8.5 Hz, 2 H, ArH), 7.2 (s, 1 H, NH), 7.4 (d, *J* = 8.5 Hz, 2 H, ArH); 13 C NMR (CDCl₃) δ 13.83, 22.39, 33.55, 33.72, 35.12, 54.14, 103.38, 116.93, 119.74, 129.01, 135.73, 138.43, 157.02, 162.43.

(±)- $(1\alpha,2\beta,3\beta,5\beta)$ -3-[2-[[4-(1-Butyl)phenyl]amino]-4-chloro-7*H*-pyrrolo[2,3-*d*]pryimidin-7-yl]-5-(hydroxymethyl)-1,2-cyclopentanediol (64)

A mixture of (±)- 4α -amino- 2β , 3β -dihydroxy- 1α -cyclopentanemethanol (obtained by the acidic hydrolysis of 3.5 g (11.18 mmol) of its tetraacetate derivative⁵⁴), **62** (3.0 g, 8.9 mmol), and Et₃N (20 mL) in 1-BuOH (100 mL) was heated under reflx for 38 h. The reaction mixture was evaporated to dryness to give crude **63**. A small amount of **63** was purified by column chromatography (CH₂Cl₂–MeOH, 95:5): 1 H NMR (DMSO- 2 d) δ 0.89 (t, 3 H, Me), 1.42 (m, 5 H, 2 × CH₂ and H-4), 2.0 (m, 2 H, H-4 and H-5), 2.5 (t, 2 H, CH₂), 2.8 (d, 1 H, H-3), 3.3 (s, 6 H, 2 × OMe), 3.4–4.0 (m, 6 H, (MeO)₂CH*CH*₂-, *CH*₂OH, H-1, and H-2), 4.2–5.2 (m, 4 H, (MeO)₂*CH* amd 3 × OH), 6.5 (d, 1 H, NH), 7.0 (d, 2 J = 8.5 Hz, 2 H, ArH), 7.6 (d, 2 J = 8.5 Hz, 2 H, ArH), 9.2 (s, 1 H, NH); 13 C NMR (DMSO- 2 d) δ 12.57, 20.53, 30.50, 32.18, 33.35, 45.51, 51.57, 52.82, 53.20, 62.41, 75.74, 77.09, 99.09, 103.53, 117.34, 126.93, 133.59, 137.17, 156.38, 161.22.

The crude **63** from the above step was dissolved in 1,4-dioxane (200 mL), and 2 N HCl (20 mL) was added to this. After stirring for 20 h at room temperature, the reaction mixture was neutrallized with concentrated NH₄OH followed by evaporation to dryness. The residue was purified by medium pressure chromatography (CH₂Cl₂–MeOH, 95:5) to give **64** (1.6 g, 42% based upon **62**) as a yellow foam, which crystallized from CH₂Cl₂: mp 172–175 °C; ¹H NMR (DMSO- d_6) δ 0.89 (t, 3 H, Me), 1.41 (m, 5 H, 2 × CH₂ and H-4′), 2.0 (m, 2 H, H-4′ and H-5′), 2.5 (m, 2 H, CH₂), 3.1 (d, 1 H, H-3′), 3.2–4.0 (m, 6 H, *CH*₂OH, H-1′, H-2′, and 2 × OH), 5.1 (d, 1 H, OH), 6.36 (d, J= 3.8 Hz, 1 H, H-7), 7.0 (d, J= 8.5 Hz, 2 H, ArH), 7.38 (d, J= 3.5 Hz, 1 H, H-8), 7.7 (d, J= 8.5 Hz, 2 H, ArH), 9.5 (br, 1 H, NH); ¹³C NMR (DMSO- d_6) δ 13.97, 21.88, 29.74, 33.53, 34.40, 45.72, 55.31, 63.44, 77.14, 78.23, 98.00, 110.14, 118.48, 127.25, 128.45, 135.00, 138.58, 150.61, 152.88, 154.83.

(±)- $(1\alpha,2\beta)$ -2-(2-Amino-6-chloro-9*H*-purin-9-yl)cyclopentan-1-ol (68)

A solution of 18.64 g (114 mmol) of 2-amino-4,6-dichloropyrimidine and 11.50 g (114 mmol) of (\pm) -trans-2-aminocyclopentanol⁵⁷ in BuOH was heated at reflux under Ar. Following the reflux period, the solvent was removed by distillation under reduced pressure and the residue treated with H_2O . The resulting beige solid was collected by filtration and washed well with H_2O followed by CHCl₃. The solid that remained was dried at 60 °C under vacuum to give 18.13 g (70%) of (\pm) - $(1\alpha,2\beta)$ -2-[(2-amino-6-chloropyrimidin-4-yl)amino]-cyclopentan-1-ol, **65**, as a tan solid, which was suficiently pure for the following step. An analytical sample was prepared by recrystallization from MeCN: mp 171–173 °C.

A solution of 3.42 g (26.85 mmol) of 4-chloroaniline in 95% EtOH (25 mL) was treated with concentrated H_2SO_4 (2.75 mL). The solution was cooled to 27 °C and treated dropwise with 1-butyl nitrite (3.2 g). The solution was then warmed carefully to 35–40 °C for 10 min

and then chilled in ice. The crystals of diazonium salt that separated were collected and washed with a minimum amount of cold EtOH and used immediately in the next step.

The diazonium salt prepared in the last step was dissolved in MeOH (30 mL) and the resulting solution treated with **65** (3.0 g, 13.12 mmol). Yellow crystals began to separate immediately. After 20 min, a solution of anhydrous AcONa (2.2 g) in H₂O (20 mL) was added and the reaction mixture then stirred for 90 min. The thick yellow paste was collected and washed well with hot MeOH. The bright yellow sample (4.10 g, 85%) of (\pm)-(1 α ,2 β)-2-[[2-amino-6-chloro-5-[(4-chlorophenyl)azo]pyrimidin-4-yl]amino]cyclopentan-1-ol, **66**, was dried under high vacuum and found to be sufficiently pure to use in the next step.

A solution of **66** (1.6 g, 4.37 mmol) and Zn (2.5 g) in a mixture of AcOH (1 mL), EtOH (60 mL), and H₂O (20 mL) was refluxed under N₂ until the yellow color disappeared. After filtration, the solvent was evaporated under reduced pressure to give a residue of (\pm)-(1 α , 2 β)-2-[(2,5-diamino-6-chloropyrimidin-4-yl)amino]cyclopentan-1-ol, **67**, which was placed in a mixture of cooled DMF (20 mL) and trimethyl orthoformate (50 mL) containing concentrated HCl (0.5 mL). This mixture was then stirred at room temperature overnight and the solvent mixture evaporated under reduced pressure. The residue was stirred in 0.5 N HCl (50 mL) for 3 h. After adjusting the pH to 9, the mixture was evaporated to dryness under reduced pressure to provide a residue that was purified by column chromatography (CH₂Cl₂:MeOH, 10:1) to give **68** as white crystals following recrystallization from MeOH (770 mg, 68.8%): mp 197–198 °C; ¹H NMR (DMSO- d_6) δ 1.5–2.2 (m, 6 H, 3 × CH₂ of cyclopentyl), 4.45 (m, 2 H, H-1 and H-2 of cyclopentyl), 6.88 (s, 2 H, NH₂), 8.21 (s, 1 H, H-8 of purine); ¹³C NMR (DMSO- d_6) δ 19.64, 28.53, 31.78, 62.55, 74.71, 123.78, 142.15, 149.27, 154.23, 159.45.

Cell Culture and Radioligand Binding

CHO cells stably expressing the A_3 receptor^{9,19} were grown in F-12 medium containing 10% FBS and penicillin/streptomycin (100 U/mL and 100 μ g/mL, respectively) at 37 °C in a 5% CO₂ atmosphere, and membrane homogenates were prepared as reported.⁹

Binding of [125 I]- N6 -(4-amino-3-iodobenzyl)adenosine-5'-(N -methyluronamide) ([125 I]AB-MECA) to the CHO cells membranes was performed essentially as described. 16,19 Assays were performed in 50/10/1 buffer in glass tubes and contained 100 μ L of the membrane suspension, 50 μ L of [125 I]AB-MECA (final concentration 0.3 nM), and 50 μ L of inhibitor. Inhibitors were routinely dissolved in DMSO and then diluted with buffer; final DMSO concentrations never exceeded 1%. Incubations were carried out in duplicate for 1 h at 37 °C and terminated by rapid filtration over Whatman GF/B filters, using a Brandell cell harvester (Brandell, Gaithersburg, MD). Tubes were washed three times with 3 mL of buffer. Radioactivity was determined in a Beckman γ -5500B counter. Nonspecific binding was determined in the presence of 40 μ M. (R)-PIA. K_i values were calculated according to the Cheng-Prusoff equation, 41 assuming a K_d for [125 I]AB-MECA of 1.55 nM. 16

Binding of [3 H]PIA (Amersham, Arlington Heights, IL) to A_1 receptors from rat brain membranes and [3 H]CGS 21680 (DuPont NEN, Boston, MA) to A_2 receptors from rat striatal membranes was performed as described previously. 17,18 Adenosine deaminase (3 U/mL) was present during the preparation of brain membranes, in which an incubation at 30 $^\circ$ C for 30 min is carried out, and during the incubation with radioligand. At least six different concentrations spanning 3 orders of magnitude, adjusted appropriately for the IC50 of each compound, were used. IC50 values, computer-generated using a nonlinear regression formula on the InPlot program (Graph-PAD, San Diego, CA), were converted to apparent K_i values using K_d values of 1.0 and 14 nM for [3 H]PIA and [3 H]CGS 21680 binding, respectively, and the Cheng–Prusoff equation. 41

GTP shifts in the displacement of the binding of [³H]-8-cyclopentyl-1,3-dipropylxanthine (CPX; DuPont NEN) were determined as described.³⁸ Adenylate cyclase measurements in A₃-transfected CHO cells were carried out as described.⁹

Acknowledgments

We thank Dr. Lars Knutsen (Novo Nordisk) for the gift of metrifudil. We are thankful to Dr. John P. Scovill (U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD), Dr. Xing Chen (University of South Florida, Tampa, currently affiliated with Schering-Plough Co., NJ), and Dr. Debra Heckendorn (U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD, currently affiliated with U.S. Naval Academy) for synthesizing compounds **12a,b.** A part of this project was supported by funds from the Department of Health and Human Services (NO1-AI-72645), and this is appreciated.

References

- Jacobson KA, van Galen P, Williams M. Adenosine receptors pharmacology, structure activity relationships, and therapeutic potential. J Med Chem. 1992; 35:407

 –422. [PubMed: 1738138]
- 2. Olsson RA, Pearson JD. Cardiovascular purinoceptors. Pharmacol Rev. 1990; 3:761-845.
- von Lubitz, DKJE.; Jacobson, KA. Behavioral effects of adenosine receptor stimulation. In: Bellardinelli, L.; Pelleg, A., editors. Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology. Kluwer; Norwell, MA: 1995. p. 489-498.
- 4. Linden J. Cloned adenosine A₃ receptors: Pharmacological properties, species differences and receptor function. Trends Pharmacol Sci. 1994; 15:298–306. [PubMed: 7940998]
- 5. Stiles GL. Adenosine receptors. J Biol Chem. 1992; 267:6451–6454. [PubMed: 1551861]
- Jacobson, M. Cloning and expression of human adenosine receptor subtypes. In: Bellardinelli, L.;
 Pelleg, A., editors. Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology. Kluwer; Norwell, MA: 1995. p. 5-13.
- Zhou QY, Li CY, Olah ME, Johnson RA, Stiles GL, Civelli O. Molecular cloning and characterization of an adenosine receptor - the A₃ adenosine receptor. Proc Natl Acad Sci USA. 1992; 89:7432–7436. [PubMed: 1323836]
- Gallo-Rodriguez C, Ji X-D, Melman N, Siegman BD, Sanders LH, Orlina J, Pu Q-L, Olah ME, van Galen PJM, Stiles GL, Jacobson KA. Structure-activity relationships at A₃-adenosine receptors. J Med Chem. 1994; 37:636–646. [PubMed: 8126704]
- van Galen PJM, van Bergen AH, Gallo-Rodriguez C, Melman N, Olah ME, IJzerman AP, Stiles GL, Jacobson KA. A binding site model and structure-activity relationships for the rat A₃ adenosine receptor. Mol Pharmacol. 1994; 45:1101–1111. [PubMed: 8022403]
- Jacobson KA, Nikodijevi O, Shi D, Gallo-Rodriguez C, Olah ME, Stiles GL, Daly JW. A role for central A₃-adenosine receptors: Mediation of behavioral depressant responses. FEBS Lett. 1993; 336:57–60. [PubMed: 8262217]
- 11. von Lubitz DKJE, Lin RCS, Popick P, Carter MF, Jacobson KA. Adenosine A₃ receptor stimulation and cerebral ischemia. Eur J Pharmacol. 1994; 263:59–67. [PubMed: 7821362]
- 12. Liu GS, Richards SC, Olsson RA, Mullane K, Walsh RS, Downey JM. Evidence that the adenosine A₃ receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res. 1994; 28:1057–1061. [PubMed: 7954592]
- Bai TR, Weir T, Walker BAM, Salvatore CA, Johnson RG, Jacobson MA. Comparison and localization of adenosine A₃ receptor expression in normal and asthmatic lung. Drug Dev Res. 1994; 31:244.
- Thompson RD, Secunda S, Daly JW, Olsson RA. N^{6,9}-Disubstituted Adenines Potent, Selective Antagonists at the A₁-Adenosine Receptor. J Med Chem. 1991; 34:2877–2882. [PubMed: 1895305]
- 15. Lohse MJ, Klotz KN, Diekmann E, Friedrich K, Schwabe U. 2',3'-Dideoxy-N⁶-cyclohexyladenosine: an adenosine derivative with antagonist properties at adenosine receptors. Eur J Pharmacol. 1988; 156:157–160. [PubMed: 3208837]

 Kim HO, Ji X-d, Melman N, Olah ME, Stiles GL, Jacobson KA. Structure activity relationships of 1,3-dialkylxanthine derivatives at rat A₃-adenosine receptors. J Med Chem. 1994; 37:3373–3382. [PubMed: 7932565]

- 17. Schwabe U, Trost T. Characterization of adenosine receptors in rat brain by (–) [³H]N⁶-phenylisopropyladenosine. Naunyn-Schmiedeberg's Arch Pharmacol. 1980; 313:179–187.
- 18. Jarvis MF, Schutz R, Hutchison AJ, Do E, Sills MA, Williams M. [3H]CGS 21680, an A₂ selective adenosine receptor agonist directly labels A₂ receptors in rat brain tissue. J Pharmacol Exp Ther. 1989; 251:888–893. [PubMed: 2600819]
- 19. Olah ME, Gallo-Rodriguez C, Jacobson KA, Stiles GL. [¹²⁵I]AB-MECA, a high affinity radioligand for the rat A₃ adenosine receptor. Mol Pharmacol. 1994; 45:978–982. [PubMed: 8190112]
- Siddiqi SM, Chen X, Schneller SW. Enantiospecific synthesis of 5'-noraristeromycin and its 7-deaza derivative and a formal synthesis of (-)-5'-homoaristeromycin. Nucleosides Nucleotides. 1993: 12:267–278.
- 21. Johnson CR, Esker JL, van Zandt MC. Chemoenzymatic Synthesis of 4-Substituted Riboses: *S*-(4-methyl adenosyl)-L-homocysteine. J Org Chem. 1994; 59:5854–5855.
- 22. Vorbrüggen H, Krolikiewicz K, Bennua B. Nucleoside synthesis with trimethylsilyl triflate and perchlorate as catalysts. Chem Ber. 1981; 114:1234–1255. and references cited therein.
- 23. (a) Chattopadhyaya JB, Reese CB. Reaction between 8-bromoadenosine and amines. Chemistry of 8-hydrazinoadenosine. Synthesis. 1977:725.(b) Ikehara M, Yamada S. Studies of Nucleosides and Nucleotides. XLIX.¹⁾ Synthesis of 8-Fluoroadenosine.²⁾. Chem Pharm Bull. 1971; 19:104–109.
- 24. (a) Siddiqi SM, Chen X, Schneller SW, Ikeda S, Snoeck R, Andrei A, Balzarini J, De Clercq E. Antiviral enantiomeric preference for 5′-noraristeromycin. J Med Chem. 1994; 37:551–554. [PubMed: 8120872] (b) Siddiqi SM, Chen X, Schneller SW, Ikeda S, Sneock R, Andrei G, Balzarini J, De Clercq E. An epimer of 5′-noraristeromycin and its antiviral properties. J Med Chem. 1994; 37:1382–1384. [PubMed: 8176716] (c) Marquez VE, Lim MI. Carbocyclic nucleosides. Med Res Rev. 1986; 6:1–40. [PubMed: 3512934]
- 25. Francis JE, Webb RL, Ghai GR, Hutchison AJ, Moskal MA, Dejesus R, Yokoyama R, Rovinski SL, Contardo N, Dotson R, Barclay B, Stone GA, Jarvis MF. Highly selective adenosine-A₂ receptor agonists in a series of N-alkylated 2-aminoadenosines. J Med Chem. 1991; 34:2570–2579. [PubMed: 1875349]
- 26. Bruns RF. Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. Can J Physiol Pharmacol. 1980; 58:673–691. [PubMed: 6253037]
- 27. (a) Kusaka T, Yamamoto H, Shibata M, Muroi M, Kishi T, Mizumo K. Streptomyces Citricolor No. Sp. and a new antibiotic aristeromycin. J Antibiot (Tokyo). 1968; 21:255–263. [PubMed: 5671989] (b) Kishi T, Muroi M, Kusaka T, Nishikawa M, Kamiya K, Mizuno K. The structure of aristeromycin. Chem Pharm Bull. 1972; 20:940–946.
- Siddiqi SM, Schneller SW, Ikeda S, Snoeck R, Andrei G, Balzarini J, De Clercq E. S-Adenosyl-L-homocysteine hydrolase inhibitors as antiviral agents: 5'-Deoxyaristeromycin. Nucleosides Nucleotides. 1993; 12:185–198.
- 29. (a) Tiwari KN, Secrist JA, Montgomery JA. Synthesis and biological activity of 4'-thionucleosides of 2-chloroadenosine. Nucleosides Nucleotides. 1994; 13:1819–1828.(b) Tiwari, KN.; Secrist, JA.; Montgomery, JA.; Masini, L. Synthesis and biological activity of 4'-thioarabinonucleosides. Submitted for publication
- 30. Thomas HJ, Tiwari KN, Clayton SJ, Secrist JA, Montgomery JA. Synthesis and biological activity of purine 2'-deoxy-2'-fluororibonucleosides. Nucleosides Nucleotides. 1994; 13:309–323.
- 31. Cristalli G, Vittori S, Eleuteri A, Volpini R, Camaioni E, Lupidi G. Synthesis of 2′-deoxyribonucleoside derivatives of 1-dezazpurine. Nucleosides Nucleotides. 1994; 13:835–848.
- 32. Cristalli G, Vittori S, Eleuteri A, Volpini R, Camaioni E, Lupidi G. Manuscript in preparation.
- 33. Wagner H, Milavec-Krizman M, Gadient F, Menninger K, Schoeffter P, Tapparelli C, Fozard JR. Drug Dev Res. 1994; 31:270.
- 34. Shuman DA, Robins RK, Robins MJ. The synthesis of adenine 5'-O-sulfamoyl nucleosides related to nucleocidin. J Am Chem Soc. 1969; 91:3931–3932. [PubMed: 5814950]

35. Cristalli G, Franchetti P, Grifantini M, Vittori S, Klotz KN, Lohse MJ. Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives. J Med Chem. 1988; 31:1179–1183. [PubMed: 3373486]

- 36. (a) Cristalli G, Eleuteri A, Vittori S, Volpini R, Lohse MJ, Klotz KN. 2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A₂ adenosine receptors. J Med Chem. 1992; 35:2363–2368. [PubMed: 1619615] (b) Cristalli G, Volpini R, Vittori S, Camaioni E, Monopoli A, Conti A, Dionisotti S, Zocchi C, Ongini E. 2-Alkynyl derivatives of adenosine-5'-N-ethyluronamide: Selective A₂ adenosine receptor agonists with potent inhibitory activity on platelet aggregation. J Med Chem. 1994; 37:1720–1724. [PubMed: 8201607]
- 37. Wildbrandt R, Frotscher U, Freyland M, Messerschmidt W, Richter R, Schulte-Lippern M, Zschaege B. Treatment of glomerulonephritis with metrifudil. Preliminary Report. Med Klin (Munich). 1972; 67(36):1138–1140.
- 38. (a) van der Wenden, EM. PhD Thesis. University of Leiden; 1994. Structural requirements for the interaction between ligands and the adenosine A₁ receptor: A search for partial agonists. (b) van der Wenden EM, vonFrijtag Drabbe Künzel JK, Mathôt RAA, IJzerman AP, Soudijn W. Ribose modified adenosine analogues as potential partial agonists for the adenosine receptor. Drug Dev Res. 1994; 31:330.
- 39. Kim HO, Ji X-d, Siddiqi SM, Olah ME, Stiles GL, Jacobson KA. 2-Substitution of N⁶-benzyladenosine-5'-uronamides enhances selectivity for A₃-adenosine receptors. J Med Chem. 1994; 37:3614–3621. [PubMed: 7932588]
- 40. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet. 1994; 2:9–13. [PubMed: 7912347]
- 41. Cheng YC, Prusoff WH. Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 percent inhibition (IC₅₀) of an enzyme reaction. Biochem Pharmacol. 1973; 22:3099–3108. [PubMed: 4202581]
- 42. Cristalli G, Grifantini M, Vittori S, Balduini W, Cattabeni F. Adenosine and 2-chloroadenosine deaza analogues as adenosine receptor antagonists. Nucleosides Nucleotides. 1985; 4:625–639.
- 43. Daly JW, Padgett WL. Agonist activity of 2- and 5'-substituted adenosine analogues and their N⁶-cycloalkyl derivatives at A₁-adenosine and A₂-adenosine receptors coupled to adenylate cyclase. Biochem Pharmacol. 1992; 43:1089–1093. [PubMed: 1554381]
- 44. Siddiqi SM, Chen X, Rao J, Schneller SW, Ikeda S, Snoeck R, Andrei G, Balzarini J, De Clercq E. 3-Deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties. J Med Chem. 1994 in press.
- 45. Iwamura H, Ito T, Kumazawa Z, Ogawa Y. Anticytokinin activity of 4-furfurylamino-7-(β-D-ribofuranosyl)pyrrolo[2,3-d]-pyrimidines. Biochem Biophys Res Commun. 1974; 57:412–416. [PubMed: 4829402]
- 46. Kazimierczuk Z, Cottam HB, Revankar GR, Robins MJ. Synthesis of 2'-deoxytubercidin, 2'-deoxyadenosine, and related 2'-deoxynucleosides via a novel direct stereospecific sodium salt glycosylation procedure. J Am Chem Soc. 1969; 91:3931–3932. [PubMed: 5814950]
- 47. Cermak RC, Vince R. (±)-4β-Amino-2α,3α-dihydroxy-1β-cyclopentanemethanol hydrochloride. Carbocyclic ribofuranosylamine for the synthesis of carbocyclic nucleosides. Tetrahedron Lett. 1981; 22:2331–2332.
- 48. Cristalli G, Vittori S, Eleuteri A, Grifantini M, Volpini R, Lupidi G, Capolongo L, Pesenti E. Purine and 1-deazapurine ribonucleosides and dexoyribonucleosides: Synthesis and biological activity. J Med Chem. 1991; 34:2226–2230. [PubMed: 2066996]
- 49. Nutt RF, Dickinson MJ, Holly FW, Walton E. Branched-Chain Sugar Nucleosides. III. 3'-C-Methyladenosine. J Org Chem. 1968; 33:1789–1759. [PubMed: 5655925]
- 50. Waga T, Nishizaki T, Miyakawa I, Ohrui O, Meguro H. Synthesis of 4'-*C*-Methylnucleosides. Biosci Biotechnol Biochem. 1993; 57:1433–1438. [PubMed: 7764216]
- 51. (a) Secrist JA III, Montgomery JA, Shealy YF, O'Dell CA, Clayton SJ. Resolution of Racemic Carbocyclic Analogues of Purine Nucleosides through the Action of Adenosine Deaminase. Antiviral Activity of the 2′-Deoxyguanosine Enantiomers. J Med Chem. 1987; 30:746–749. [PubMed: 3031295] (b) Herdewijn P, Balzarini J, De Clerq E, Vanderhaeghe H. Resolution of Aristeromycin Enantiomers. J Med Chem. 1985; 28:1385–1386. [PubMed: 4045916]

52. Chen X, Siddiqi SM, Schneller SW, Snoeck R, Balzarini J, De Clercq E. Synthesis and Antiviral Properties of Carbocyclic 3'-Oxa-2',3'-dideoxyguanosine and Its 7-Deazaguanosine Analogue. Antiviral Res. 1993; 20:333–345. [PubMed: 8387261]

- Seela F, Bussmann W, Götze A, Rosemeyer H. Isomeric N-methyl-7-deazaguanosines: Synthesis, Structural Assignment, and Inhibitory Activity on Xanthine Oxidase. J Med Chem. 1984; 27:981–985. [PubMed: 6547745]
- 54. Vince R, Brownell J, Daluge S. Carbocyclic Analogues of Xylofuranosylpurine Nucleosides. Synthesis and Antitumor Activity. J Med Chem. 1984; 27:1358–1362. [PubMed: 6481772]
- 55. Schneller, SW.; Chen, X.; Siddiqi, SM. Carbocyclic 7-Deazaguanosine Nucleosides As Antiviral Agents. In: Chu, CK.; Baker, DC., editors. Nucleosides and Nucleitides as Antitumor and Antiviral Agents. Plenum Press; New York: 1993. p. 141-158.
- 56. Patil SD, Schneller SW. (\pm) -5'-Nor Ribofuranoside Carbocyclic Guanosine. J Heterocycl Chem. 1991; 28:823–825.
- 57. McCasland GE, Smith DA. Stereochemistry of Aminocyclanols. Synthesis of *cis*-Epimers via Oxazolines. The 2-Aminocyclopentanols. J Am Chem Soc. 1950; 72:2190–2195.




Figure 1. Inhibition of adenylate cyclase in membranes from CHO cells stably transfected with rat A_3 receptors. The assay was carried out as described in the Experimental Section in the presence of 1 mM forskolin. Each data point is shown as the mean \pm SEM for four determinations. Adenosine derivatives were (number of separate experiments in parentheses) triangles, 41, N^6 -benzyl-4'-methyladenosine-5'-(N-methyluronamide); circles, 2-chloro- N^6 -(3-iodobenzyl)adenosine-5'-(N-methyluronamide); and squares, NECA. IC₅₀ values were Cl-IB-MECA, 66.8 ± 9.0 nM; NECA, 3 μ M; and 41, 10 μ M.

Scheme 1.

Synthesis of Compound 12c^a

^aReaction conditions: (a) (i) NaH, 2,6-dichloropurine, THF, 0 °C; (ii) Pd(PPh₃)4, PPh₃, 45, THF, 50 °C; (b) OsO₄, *N*-methylmorpholine *N*-oxide, THF/H₂O; (c) NH₄OH, MeOH; (d) phenylethylamine, EtOH, Et₃N, reflux.

Scheme 2.
Synthesis of Uronamide 41^a

^aReaction conditions: (a) MeNH₂, MeOH; (b) (i) HCl, MeOH, (ii) Ac₂O, py; (c) N-TMS-6-Cl-purine, TMS-OTf, CH₃CN; (d) (i) NH₃, MeOH, 0 °C, (ii) BnNH₂, t-BuOH.

Scheme 3. Synthesis of Carbocyclic IB-MECA, **44**^a

^aReaction conditions: (a) MeNH₂, THF, heat; (b) 5-amino-4,6-dichloropyrimidine, *n*-BuOH, Et₃N; (c) (i) (MeO)₂CHOAc, reflux, (ii) 1 N HCl; (d) 3-I-PhCH₂NH₂·HCl, Et₃N, EtOH, heat.

Scheme 4. Synthesis of Compound 12a^a

^aReaction conditions: (a) (±*trans*-2-aminocyclopentanol,⁵⁷ reflux in 1-BuOH; (b) (4-chlorophenyl)diazonium chloride; (c) Zn in AcOH/EtOH/H₂O, reflux; (d) (MeO)₃CH, concentrated HCl; (e) NH₃ in MeOH.

ArNH
$$^{\circ}_{NH_2}$$
 EtO₂C $^{\circ}_{ArHN}$ $^{\circ}_{NH_2}$ EtO₂C $^{\circ}_{ArHN}$ $^{\circ}_{NH_2}$ $^{\circ}_{S8}$ $^{\circ}_{ArHN}$ $^{\circ}_{NH_2}$ $^{\circ}_{S9}$ $^{\circ}_{60, X = Cl}$ $^{\circ}_{S9}$ $^{\circ}_{61, R = O}$ $^{\circ}_{S9}$ $^{\circ}_{61, R = O}$ $^{\circ}_{S9}$ $^{\circ}_{62, R = (MeO)_2}$ $^{\circ}_{S9}$ $^{\circ}_{63}$ $^{\circ}_{S9}$ $^{\circ}_{64, X = Cl}$ $^{\circ}_{S9}$

Scheme 5. Synthesis of 2-[[4-(1-Butyl)phenyl]amino]-*ara*-aristeromycin, **15b**^a ^aReaction conditions: (a) NaOEt, EtOH; (b) POCl₃, Et₄NCl, N,N-diethylaniline in MeCN, 70 °C then 100 °C; (c) OsO₄, NaIO₄ in MeOH, acetone, H₂O; (d) NH₄Cl, pyridinium p-toluenesulfonate in absolute MeOH; (e) (\pm)-4a-amino-2 β ,3 α -dihydroxy-1 α -cyclopentanemethanol⁵⁴ in n-BuOH containing ET₃N, heat; (f) 2 N HCl in 1,4-dioxane; (g)

NH₃-MeOH, heat.

Siddiqi et al. Page 25

Table 1

Affinities of Adenosine Derivatives in Radioligand Binding Assays at Rat Brain A₁, A_{2a}, and A₃ Receptors^{a-c,g}

		ģ		Reference 9	42		43	6	23,38
11, 1224, 411		M + 10 + 7		$\frac{\mathbf{K_{i}(A_{2})}^{c}}{1.89d}$	2.48±0.36		10.4 ± 2.3	31% d	26%
	HOCH ₂ O	HO OH	, , , , , , , , , , , , , , , , , , ,	$\frac{\mathbf{K}_{\mathbf{i}}(\mathbf{A}_{2\mathbf{a}})^{\boldsymbol{\nu}}}{0.063}$	0.163 ± 0.040		0.028	22.7	24.1
a. Non-N ⁶ -substituted Derivatives	ĭ	Rib=		$\frac{\mathbf{K}_{\mathbf{i}}(\mathbf{A}_{\mathbf{l}})^{a}}{0.0093}$	0.226 ± 0.028		0.0059	41%	53% h
a. Non-N ⁶ -subst		:— z	ŝ	<u>R</u> 3=	,		П		•
a. Non-N ⁶ -substituted Derivatives	R ₂ -	A =		Structure A-Rib	Í	z	A-Rib	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
				Compound 1	71		8	4	w

		a. Non-N ⁶ -substituted Derivatives	ıted Derivative	S		
		₹ <u></u> ~	ī	-		
	R ₂ -					
	A=		Rib≕	-0 -0 -0		
			, K	K_{j} (μM) or % displacement at 10^{-4} $M\!S$	ment at 10^{-4} N	<u> 20</u>
Compound	Structure	$\overline{\mathbf{R}}_{2}$ =	$\overline{\mathbf{K}_{\mathbf{i}}(\mathbf{A}_{\underline{1}})^d}$	$\overline{\mathrm{K}_{\mathrm{i}}(\mathrm{A}_{2\mathrm{a}})}^{b}$	$\overline{\mathrm{K}_{\overline{\mathrm{i}}}(\mathrm{A}_{\overline{3}})^{\mathcal{C}}}$	Reference
9	NH2 N (CH2)3CH3	•	11.4 <i>h</i>	11.5	31%	23,38
7	носн,	Н	3±1%	%0	200±8	ı
	Į.					
œ	√ CH3	Н	0.269	0.596	2.83 <i>d</i>	6
	HO OH					
6	CH ₃	н	12±4%	4.30±0.41	66±2%	28
	HO OH					
10a	√- \ \ \	Н	33.0±6.8	0.692 ± 0.096	68 ±1%	20,24
	-0H					

		a. Non-N ⁶ -substituted Derivatives	uted Derivatives			
	Œ.		ĭ	HOCH		
	A=	: z	Rib=	HO OH		
			$\overline{\mathbf{K}_{\mathbf{i}}}$ ($\overline{K_{j}}$ (μM) or % displacement at $10^{-4} \overline{M}^{g}$	ement at 10^{-4} N	8
Compound	Structure	$\overline{\mathbf{R}}_{\underline{2}} =$	$\overline{\mathrm{K}_{\underline{\mathrm{i}}}(\mathrm{A}_{\underline{\mathrm{I}}})^{a}}$	$\overline{{\rm K_{\bar{i}}}({\rm A}_{2{\rm a}})}b$	$\overline{\mathrm{K}_{\mathrm{i}}(\mathrm{A}_{\mathrm{2}})^{\mathcal{C}}}$	Reference
10b	∀	Н	37±7%	41.4 ± 11.0	122 ± 17	24b
Ξ	P. P	φ-(CH ₂) ₂ NH-	$0.98^{\mathcal{C}}$ (IC ₅₀)	0.068^f (IC $_{50}$)		25
12a	₹	$^{ m ZH}_2$	30±1%	20.8±3.7	199±26	1
12b	£ _	$^{ m NH}_2$	%0	16±5%	198±33	52
120/	\$ \$\frac{1}{2} \frac{1}{2} \fr	φ-(CH ₂) ₂ NH-	0.946±0.179	$1.82{\pm}0.20^{j}$	59.2±9.2	1

a. Non-N ⁶ -substituted Derivatives	
a. Non-N	

		a. Non-N ⁶ -substituted Derivatives	ıted Derivatives			
	ا ش	z^ <u>z</u>	ĭ	HOCH ₂ O		
	A =	z z	ajb=	Γş		
			K	$K_{ m j}$ ($\mu { m M}$) or % displacement at $10^{-4} { m Mg}$	ement at 10^{-4} $\overline{\mathrm{M}}$	20
Compound	Structure	$\overline{\mathbf{R}_2}$ =	$\overline{\mathbf{K}_{\underline{\mathbf{i}}}(\mathbf{A}_{\underline{1}})^{\boldsymbol{d}}}$	$\overline{{\bf K}_{\rm i}({\bf A}_{2{\bf a}})}b$	$\overline{\mathrm{K}_{\mathrm{i}}(\mathrm{A}_{\underline{3}})^{\mathcal{C}}}$	Reference
15b	HANDER OF THE PROPERTY OF THE		29±6%	11 ±2%	70.4±2.2	ı
16′			%0	%	%61	20.44
17	4 of the second	н	29.0	25%	10% d	6
81	چ چ چ	н	180±40	8.54±1.77	24±1%	24

		a. Non-N ⁶ -substituted Derivatives	nted Derivatives			
	E.	z^z <u>x</u>	ĭ	HOCHE		
	A =	:— •	Rib=	HO OH		
			$\mathbf{K}_{\mathbf{i}}$	K_{i} (µM) or % displacement at 10^{-4} M8	ment at $10^{-4}\mathrm{M}$	60 .
Compound	Structure	$\overline{\mathbf{R}_2}$ =	$\overline{\mathbf{K}_{\mathbf{i}}(\mathbf{A}_{\underline{1}})^{\mathcal{G}}}$	$\overline{\mathrm{K}_{\mathrm{i}}}(\overline{\mathrm{A}_{2\mathrm{a}}})^{b}$	$\overline{\mathrm{K}_{\underline{\mathbf{i}}}(\mathrm{A}_{\underline{\mathbf{j}}})^{\mathcal{C}}}$	Reference
61	HOCH'S S	ō	0.300 ± 0.053	0.0198 ±0.0046	1.09±0.11	29
20	POCH P	Ħ	20%	26%	24% d	6
21	POCH ₂ %	D D	5.36±0.87	7.12±1.36	49.3±2.2	29
22	S CH ₂ OH	ō	7.99±1.38	12.8±2.4	32%	29
23	400 P	ū	0.640 ±0.107	0.897 ± 0.178	82.4±5.2	30

	a. Non-N ⁶ -substituted Derivatives	ted Derivatives			
(Ŧ	HOCH ₂ O		
. ₩	\z_ \z \z 	Rib₌	导		
		$\overline{\mathbf{K}_{\mathbf{i}}}$ ($\overline{K_{ m i}}$ ($\mu m M$) or % displacement at $10^{-4} m M$	ement at 10 ⁻⁴ M	<u>ec.</u>
Structure	$\overline{\mathbf{R}_2}$ =	$\overline{\mathbf{K}_{\underline{\mathbf{i}}}(\mathbf{A}_{\underline{1}})^{\boldsymbol{d}}}$	$\overline{\mathrm{K}_{\mathrm{i}}}(\overline{\mathrm{A}_{2\mathrm{a}}})^{b}$	$\overline{\mathrm{K}_{\overline{\mathbf{i}}}(\mathrm{A}_{\underline{\mathbf{j}}})^{\mathcal{C}}}$	Reference
POCH" OCH"	王	31%	39%	28% d	6
Poort of the second of the se	ਹ	7.32±0.96	20.4±3.5	207±8	46
A CONTRACTOR OF THE PROPERTY O	,	29.0±4.4	35±3%	21%	31
TO CHOOCH	•	101±19	55.5±2.8	16%	32

		a. Non-N ⁶ -substituted Derivatives	nted Derivatives			
	•	Z Z	ĭ	HOCH ₂ O		
	A R2-	`z— { Z	Rib=	塔		
			<u>K</u> ,	$ m K_{ m i}$ ($\mu m M$) or % displacement at 10 $^{-4}$ M $^{ m s}$	ement at 10^{-4} M	<i>5</i> €.
Compound	Structure	$\underline{\mathbf{R}}_{\underline{2}} =$	$\overline{\mathrm{K}_{\mathrm{i}}(\mathrm{A}_{1})^{d}}$	$\overline{\mathrm{K}_{\mathrm{i}}}(\mathrm{A}_{\underline{\mathrm{2a}}})^{b}$	$\overline{\mathrm{K_{i}}(\mathrm{A_{\bar{2}}})^{\mathcal{C}}}$	Reference
28a	HOCH ₂ OCH ₃	н	29%	49%	43% d	6
28b	400 H	ш	%0	%8	11%	1
29a	₹ • • • • •	ш	51.0±5.5	13%	%6	49
29b	40°CH, 0°CH,	ш	3%	%0	%8	50
30/	H ₂ NSO ₂ OCH ₂ OO	ш	1.03±0.05	5.00±1.63	11.0±1.9	34

		a. Non-N ⁶ -substituted Derivatives	ited Derivative	Ş		
		NHZ-		-		
	P ₂ -	z^z)_(v_z z-/	I	P P P P P P P P P P P P P P P P P P P		
	A=	 :	Rib∍	-0 -0 -0		
			K	(µM) or % displ	K_{j} (μM) or % displacement at 10^{-4} \overline{M}^{g}	50
Compound	Structure	$\overline{\mathbf{R}}_{\underline{2}}=$	$\overline{\mathbf{K}_{\underline{\mathbf{i}}}(\mathbf{A}_{\underline{1}})^{d}}$	$\overline{\mathrm{K_{i}}(\mathrm{A}_{2\mathrm{a}})^{b}}$	$\overline{\mathbf{K_{\overline{i}}}(\mathbf{A_{\overline{3}}})^{\mathcal{C}}}$	Reference
31	CH3CH2NHCO O	н	0.063	0.0103	0.113^{d}	6
	Iş					
32	N-	ı	0.051	0.58^f	0.703 ± 0.035	35
	CH3CH2NHCO O					
	구 _호					
33	CH3CH2NHCO O	C≡C-(CH ₂) ₃ CH ₃	0.130^{e}	0.0022	0.0256 ± 0.0032	36
	Į.					

b. N⁶-Substituted Derivatives

Compound
34
35

 0.742 ± 0.312 0.604 ± 0.143 56% (10⁻⁴) $\overline{\mathrm{K}_{\mathrm{i}}(\mathrm{A}_{\mathrm{3}})^{\mathcal{C}}}$ 16.9 ± 1.3 1.48 ± 0.41 0.120^{d} 0.016^{d} $0.0241 \pm\! 0.0018$ 0.129 ± 0.039 0.293 ± 0.077 53.6 ± 14.6 7.34 ± 1.12 0.597 10 0.0596 ± 0.0143 0.236 ± 0.005 0.042 ± 0.013 29.7±6.6 $\overline{\mathbf{K}_{\mathbf{i}}(\mathbf{A}_{\mathbf{1}})^{a}}$ 62.4 ± 6.1 0.120 9.4^{h} ϕCH_{2} - $\overline{\mathbf{R}}_{\underline{6}} =$ H_2N_- Structure A-Rib A-Rib A-Rib A-Rib CH3NHCO A-Rib

36

39

2

41

38

		ğ	
	•		
		2	
	•	į	
	í	9	
	,	9	
	,		
	•	į	,
	•		
	ζ	,	
١		2	
		_	
		c	

		Reference		∞	ı
		$\overline{\mathrm{K}_{\mathrm{i}}(\mathrm{A}_{\mathrm{3}})}^{c}$	0.720 ±0.250	0.0011	19.5 ±4.7
HOCH ₂ O	Γ _ξ	$\overline{\mathrm{K_{i}}(\mathrm{A}_{2\mathrm{a}})}^{b}$	6.22 ±2.71	0.056	28±5%
H	Rib=	$\overline{\mathrm{K}_{\mathrm{i}}(\mathrm{A}_{\underline{1}})^{d}}$	8.61 ±2.55	0.054	35.9 ± 8.3
AH / - /	z	$\overline{\mathbf{R}}_{\underline{6}} =$	CH2 CH2	ş Ţ	हैं
_	A=	Structure	CH3NHCO OH	CH ₃ NHCO OH	CH ₃ NHCO HO HO HO HO HO HO HO HO HO HO HO HO HO
		Compound	42	43	4

^aDisplacement of specific [³H]PIA binding, unless noted, in rat brain membranes expressed as $K_1 \pm \text{SEM}$ in μM (n = 3 - 6), or as a single average value if from a literature report.

bisplacement of specific [3 H]CGS 21680 binding, unless noted, in rat striatal membranes expressed as $K_1 \pm SEM$ in μM (n = 3 - 6), or as a single average value if from a literature report.

^CDisplacement of specific binding of [1251]-N⁶-(4-amino-3-iodobenzyl)adenosine-5'-(N-methyluronamide), ¹⁹ unless noted, in membranes of CHO cells stably transfected with the rat A3-cDNA expressed as $K_{\rm I} \pm {\rm SEM}$ in $\mu{\rm M}$ (n=3-7). d Displacement of specific binding of [125 I]- 16 -(4-amino-3-iodophenethyl)adenosine 9 in membranes of CHO cells stably transfected with the rat A3-cDNA expressed as $K_1 \pm \text{SEM}$ in μ M (n = 3-5).

e) bisplacement of specific [3H]-N6-cyclohexyladenosine binding in rat brain membranes,

 $f_{\rm Displacement}$ of specific $f^3H_1-5'-({\rm Wethylcarbamoyl})$ adenosine binding in rat striatal membranes.

 Z When a percentage is given, it refers to the percent displacement of radioligand binding at 10^{-4} M.

 h Displacement of specific [3 H]-8-cyclopentyl-1,3-dipropylxanthine binding in rat brain membranes.

/Radioligand binding increased at 10⁻⁴ M.

 Table 2

 Characterization of Newly Synthesized Compounds

comp no.	formula	analysis	mp (°C)
12a	$C_{10}H_{14}N_6O$	C, H, N	214–215
12c	$C_{18}H_{22}N_6O_3$	C, H, N	200
15b	$C_{22}H_{29}N_5O_3\cdot 2 H_2O$	C, H, N	210–213
21	$C_{10}H_{12}ClN_5O_3S$	C, H, N	207
22	$C_{10}H_{12}ClN_5O_2S$	C, H, N	171–173
39	$C_{19}H_{22}N_5O_6\cdot 0.5 H_2O$	C, H, N	176–178
41	$C_{19}H_{22}N_6O_4$	C, H	125-130 (dec)
42	$C_{16}H_{17}N_6O_5$	C, H, N	200-203
44	$C_{19}H_{21}IN_6O_3$	C, H, N	foam
46	$C_{10}H_8Cl_2N_4O$	C, H, N	foam
48	$C_{10}H_{12}ClN_5O_3$	C, H, N	180
50	$C_{11}H_{19}NO_5$	C, H	oil
β-51	$C_{12}H_{19}NO_7$	C, H	oil
52	$\mathrm{C}_{16}\mathrm{H}_{18}\mathrm{ClN}_5\mathrm{O}_6$	C, H	foam
57	$C_{12}H_{14}ClN_5O_3$	C, H, N	foam
58	$C_{17}C_{21}N_3O_2 \cdot H_2O$	C, H, N	211–212
60	$C_{17}H_{19}Cl_2N_3$	C, H, N	70–72
61	$C_{16}H_{17}Cl_2N_3O$	C, H, N	80
62	$C_{18}H_{23}Cl_2N_3O_2$	C, H, N	52–55
64	$\mathrm{C}_{22}\mathrm{H}_{27}\mathrm{ClN}_4\mathrm{O}_3{\cdot}\mathrm{H}_2\mathrm{O}$	C, H, N	172–175
65	$C_9H_{13}CIN_4O$	C, H, N	171–173
66	$C_{15}H_{16}Cl_2N_6O$	C, H, N	
68	$\mathrm{C}_{10}\mathrm{H}_{12}\mathrm{ClN}_5\mathrm{O}$	C, H, N	197–198

Table 3

Displacement of the Antagonist Radioligand $[^3H]$ CPX and the Degree of Shift of the Displacement Curve in the Presence of 1 mM GTP

	$K_{ m i}$ value (μ M) or % displacement at $10^{-4}{ m M}^a$		
compd	A ₁ (-GTP)	A ₁ (+ GTP)	GTP Shift b
10a	40	nd	
12c	35	nd	
18	36	nd	
21	13	30	2.3
22	8.4	12	1.4
23	1.7	8.3	4.9
25	12	21	1.7
26	31	nd	
27	37	nd	
28b	12	nd	

^aAverage of two determinations.

nd = not determined.

 $^{^{}b}$ Ratio of K_{1} values in the presence and absence of GTP.